株探米国株
英語
エドガーで原本を確認する
false Q1 2025 --09-30 0001855467 P1Y http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember P5Y 0001855467 2024-10-01 2024-12-31 0001855467 MOBX:ClassCommonStockParValue0.00001PerShareMember 2024-10-01 2024-12-31 0001855467 MOBX:RedeemableWarrantsEachWarrantExercisableForOneShareOfClassCommonStockMember 2024-10-01 2024-12-31 0001855467 us-gaap:CommonClassAMember 2025-01-31 0001855467 us-gaap:CommonClassBMember 2025-01-31 0001855467 2024-12-31 0001855467 2024-09-30 0001855467 us-gaap:NonrelatedPartyMember 2024-12-31 0001855467 us-gaap:NonrelatedPartyMember 2024-09-30 0001855467 us-gaap:RelatedPartyMember 2024-12-31 0001855467 us-gaap:RelatedPartyMember 2024-09-30 0001855467 us-gaap:CommonClassAMember 2024-12-31 0001855467 us-gaap:CommonClassAMember 2024-09-30 0001855467 us-gaap:CommonClassBMember 2024-12-31 0001855467 us-gaap:CommonClassBMember 2024-09-30 0001855467 2023-10-01 2023-12-31 0001855467 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001855467 MOBX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001855467 MOBX:ContingentlyRedeemableCommonStockMember 2024-09-30 0001855467 MOBX:LegacyCommonStockMember 2024-09-30 0001855467 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-09-30 0001855467 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-09-30 0001855467 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001855467 us-gaap:RetainedEarningsMember 2024-09-30 0001855467 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001855467 MOBX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001855467 MOBX:ContingentlyRedeemableCommonStockMember 2023-09-30 0001855467 MOBX:LegacyCommonStockMember 2023-09-30 0001855467 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-09-30 0001855467 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-09-30 0001855467 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001855467 us-gaap:RetainedEarningsMember 2023-09-30 0001855467 2023-09-30 0001855467 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-10-01 2024-12-31 0001855467 MOBX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-10-01 2024-12-31 0001855467 MOBX:ContingentlyRedeemableCommonStockMember 2024-10-01 2024-12-31 0001855467 MOBX:LegacyCommonStockMember 2024-10-01 2024-12-31 0001855467 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001855467 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001855467 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001855467 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001855467 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-10-01 2023-12-31 0001855467 MOBX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-10-01 2023-12-31 0001855467 MOBX:ContingentlyRedeemableCommonStockMember 2023-10-01 2023-12-31 0001855467 MOBX:LegacyCommonStockMember 2023-10-01 2023-12-31 0001855467 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001855467 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001855467 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001855467 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001855467 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001855467 MOBX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001855467 MOBX:ContingentlyRedeemableCommonStockMember 2024-12-31 0001855467 MOBX:LegacyCommonStockMember 2024-12-31 0001855467 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-12-31 0001855467 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-12-31 0001855467 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001855467 us-gaap:RetainedEarningsMember 2024-12-31 0001855467 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001855467 MOBX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001855467 MOBX:ContingentlyRedeemableCommonStockMember 2023-12-31 0001855467 MOBX:LegacyCommonStockMember 2023-12-31 0001855467 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001855467 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-12-31 0001855467 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001855467 us-gaap:RetainedEarningsMember 2023-12-31 0001855467 2023-12-31 0001855467 2023-12-21 2023-12-21 0001855467 2023-12-21 0001855467 us-gaap:CommonClassAMember 2023-12-21 0001855467 srt:MinimumMember 2024-12-31 0001855467 srt:MaximumMember 2024-12-31 0001855467 MOBX:LegacyMobixMember us-gaap:CommonClassAMember 2024-12-31 0001855467 MOBX:LegacyMobixMember us-gaap:CommonClassBMember 2024-12-31 0001855467 us-gaap:CommonClassAMember MOBX:LegacyMobixMember 2024-10-01 2024-12-31 0001855467 us-gaap:CommonClassAMember MOBX:PIPESubscriptionAgreementsMember 2024-10-01 2024-12-31 0001855467 us-gaap:CommonClassAMember MOBX:PIPESubscriptionAgreementsMember 2024-12-31 0001855467 MOBX:PIPESubscriptionAgreementsMember 2024-12-31 0001855467 MOBX:SponsorPIPESubscriptionAgreementMember 2023-12-19 0001855467 MOBX:SponsorPIPESubscriptionAgreementMember MOBX:LegacyMobixMember 2024-10-01 2024-12-31 0001855467 MOBX:SponsorPIPESubscriptionAgreementMember MOBX:LegacyMobixMember 2024-12-31 0001855467 MOBX:LegacyMobixMember us-gaap:CommonClassAMember MOBX:SponsorPIPESubscriptionAgreementMember 2024-10-01 2024-12-31 0001855467 MOBX:SponsorPIPESubscriptionAgreementMember 2023-12-20 2023-12-20 0001855467 MOBX:SponsorPIPESubscriptionAgreementMember 2023-12-20 0001855467 MOBX:FounderSharesMember 2023-12-20 2023-12-20 0001855467 MOBX:PrivateWarrantsMember 2023-12-20 2023-12-20 0001855467 2023-12-20 0001855467 us-gaap:WarrantMember 2023-12-20 2023-12-20 0001855467 MOBX:NonRedemptionAgreementMember 2023-12-20 2023-12-20 0001855467 MOBX:NonRedemptionAgreementMember us-gaap:CommonClassAMember 2023-12-20 2023-12-20 0001855467 us-gaap:CommonClassAMember 2023-12-21 2023-12-21 0001855467 MOBX:EarnoutSharesMember 2024-10-01 2024-12-31 0001855467 MOBX:EarnoutSharesMember 2024-12-31 0001855467 MOBX:EarnoutSharesMember us-gaap:CommonClassAMember 2024-12-31 0001855467 MOBX:EarnoutSharesMember 2023-10-01 2023-12-31 0001855467 MOBX:MakeWholeSharesMember us-gaap:CommonClassAMember 2024-12-31 0001855467 MOBX:MakeWholeSharesMember us-gaap:CommonClassAMember 2024-10-01 2024-12-31 0001855467 MOBX:MakeWholeSharesMember 2024-10-01 2024-12-31 0001855467 MOBX:LegacyMobixMember 2024-12-31 0001855467 MOBX:LegacyMobixMember 2024-10-01 2024-12-31 0001855467 MOBX:ChavantPublicSharesNetOfRedemptionsMember 2023-10-01 2023-12-31 0001855467 MOBX:ChavantFounderSharesNetOfSharesForfeitedMember 2023-10-01 2023-12-31 0001855467 MOBX:PIPEInvestorsSharesMember 2023-10-01 2023-12-31 0001855467 MOBX:SettlementOfPIPEWarrantMember 2023-10-01 2023-12-31 0001855467 MOBX:SponsorPIPESubscriptionMember 2023-10-01 2023-12-31 0001855467 MOBX:SettlementOfSponsorWarrantMember 2023-10-01 2023-12-31 0001855467 MOBX:SettlementOfWarrantToNonRedeemingShareholderMember 2023-10-01 2023-12-31 0001855467 MOBX:AmendmentToBusinessCombinationMarketingAgreementMember 2023-10-01 2023-12-31 0001855467 MOBX:ChavantSharesOutstandingImmediatelyPriorToTheMergerMember 2023-10-01 2023-12-31 0001855467 MOBX:LegacyMobixRolloverSharesMember 2023-10-01 2023-12-31 0001855467 MOBX:ConversionOfLegacyMobixConvertibleNotesMember 2023-10-01 2023-12-31 0001855467 MOBX:ConversionOfLegacyMobixSAFEsMember 2023-10-01 2023-12-31 0001855467 MOBX:LegacyMobixMember 2023-10-01 2023-12-31 0001855467 MOBX:ChavantMember 2023-10-01 2023-12-31 0001855467 MOBX:EarnoutLiabilityMember 2023-10-01 2023-12-31 0001855467 MOBX:PIPEMakeWholeLiabilityMember 2023-10-01 2023-12-31 0001855467 MOBX:PrivateWarrantsMember 2023-10-01 2023-12-31 0001855467 MOBX:EMISolutionsIncMember 2024-10-01 2024-12-31 0001855467 MOBX:RaGESystemsIncMember 2024-10-01 2024-12-31 0001855467 MOBX:EMISolutionsIncMember 2024-12-31 0001855467 MOBX:RaGESystemsIncMember 2024-12-31 0001855467 MOBX:EMISolutionsIncMember us-gaap:CustomerRelationshipsMember 2024-12-31 0001855467 MOBX:RaGESystemsIncMember us-gaap:CustomerRelationshipsMember 2024-12-31 0001855467 MOBX:EMISolutionsIncMember us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0001855467 MOBX:RaGESystemsIncMember us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0001855467 MOBX:EMISolutionsIncMember MOBX:BacklogMember 2024-12-31 0001855467 MOBX:RaGESystemsIncMember MOBX:BacklogMember 2024-12-31 0001855467 MOBX:EMISolutionsIncMember MOBX:TradeNameMember 2024-12-31 0001855467 MOBX:RaGESystemsIncMember MOBX:TradeNameMember 2024-12-31 0001855467 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001855467 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2024-12-31 0001855467 MOBX:LegacyMobixMember 2024-12-31 0001855467 us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001855467 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001855467 srt:ScenarioForecastMember 2025-04-15 0001855467 MOBX:RageSystemsMember 2024-10-01 2024-12-31 0001855467 MOBX:RageSystemsMember 2023-10-01 2023-12-31 0001855467 MOBX:EquipmentAndFurnitureMember 2024-12-31 0001855467 MOBX:EquipmentAndFurnitureMember 2024-09-30 0001855467 MOBX:EquipmentAndFurnitureMember srt:MinimumMember 2024-12-31 0001855467 MOBX:EquipmentAndFurnitureMember srt:MaximumMember 2024-12-31 0001855467 MOBX:LaboratoryEquipmentMember 2024-12-31 0001855467 MOBX:LaboratoryEquipmentMember 2024-09-30 0001855467 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001855467 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001855467 us-gaap:DevelopedTechnologyRightsMember srt:MinimumMember 2024-12-31 0001855467 us-gaap:DevelopedTechnologyRightsMember srt:MaximumMember 2024-12-31 0001855467 us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0001855467 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001855467 us-gaap:CustomerRelationshipsMember srt:MinimumMember 2024-12-31 0001855467 us-gaap:CustomerRelationshipsMember srt:MaximumMember 2024-12-31 0001855467 us-gaap:CustomerRelationshipsMember 2024-12-31 0001855467 us-gaap:CustomerRelationshipsMember 2024-09-30 0001855467 us-gaap:TradeNamesMember srt:MinimumMember 2024-12-31 0001855467 us-gaap:TradeNamesMember srt:MaximumMember 2024-12-31 0001855467 us-gaap:TradeNamesMember 2024-12-31 0001855467 us-gaap:TradeNamesMember 2024-09-30 0001855467 MOBX:BacklogMember 2024-12-31 0001855467 MOBX:BacklogMember 2024-09-30 0001855467 us-gaap:CustomerRelationshipsMember 2024-10-01 2024-12-31 0001855467 us-gaap:TradeNamesMember 2024-10-01 2024-12-31 0001855467 us-gaap:RelatedPartyMember MOBX:SevenPercentagePromissoryNotesMember 2024-12-31 0001855467 us-gaap:RelatedPartyMember MOBX:SevenPercentagePromissoryNotesMember 2024-09-30 0001855467 srt:BoardOfDirectorsChairmanMember 2024-12-31 0001855467 srt:BoardOfDirectorsChairmanMember 2024-10-01 2024-12-31 0001855467 MOBX:PurchaseAndSaleAgreementMember 2024-12-01 2024-12-31 0001855467 MOBX:PurchaseAndSaleAgreementMember MOBX:WeeklyInstallmentsMember srt:MinimumMember 2024-12-01 2024-12-31 0001855467 MOBX:PurchaseAndSaleAgreementMember MOBX:WeeklyInstallmentsMember srt:MaximumMember 2024-12-01 2024-12-31 0001855467 us-gaap:CommonClassAMember 2024-10-01 2024-12-31 0001855467 MOBX:TwoPromissoryNotesMember 2023-12-31 0001855467 MOBX:TwoPromissoryNotesMember 2023-10-01 2023-12-31 0001855467 MOBX:OtherNotesMember us-gaap:RelatedPartyMember 2023-12-31 0001855467 MOBX:TwoPromissoryNotesMember us-gaap:RelatedPartyMember 2024-12-31 0001855467 MOBX:TwoPromissoryNotesMember us-gaap:RelatedPartyMember 2024-10-01 2024-12-31 0001855467 MOBX:OnePromissoryNotesMember us-gaap:RelatedPartyMember 2024-10-31 0001855467 MOBX:OnePromissoryNotesMember us-gaap:RelatedPartyMember 2024-12-31 0001855467 us-gaap:RelatedPartyMember 2024-10-01 2024-12-31 0001855467 us-gaap:RelatedPartyMember 2023-10-01 2023-12-31 0001855467 MOBX:SimpleAgreementsForFutureEquityMember us-gaap:CommonClassAMember 2024-12-31 0001855467 MOBX:SimpleAgreementsForFutureEquityMember us-gaap:CommonClassAMember 2024-10-01 2024-12-31 0001855467 MOBX:ConvertibleNotesMember MOBX:UnaffiliatedInvestorsMember 2023-12-31 0001855467 MOBX:ConvertibleNotesMember MOBX:UnaffiliatedInvestorsMember us-gaap:CommonClassAMember 2023-10-01 2023-12-31 0001855467 MOBX:PromissoryNotesRelatedPartiesMember 2024-12-31 0001855467 MOBX:PromissoryNotesRelatedPartiesMember 2023-09-30 0001855467 us-gaap:FairValueInputsLevel1Member MOBX:EarnoutLiabilityMember 2024-10-01 2024-12-31 0001855467 us-gaap:FairValueInputsLevel2Member MOBX:EarnoutLiabilityMember 2024-10-01 2024-12-31 0001855467 us-gaap:FairValueInputsLevel3Member MOBX:EarnoutLiabilityMember 2024-10-01 2024-12-31 0001855467 MOBX:EarnoutLiabilityMember 2024-10-01 2024-12-31 0001855467 us-gaap:FairValueInputsLevel1Member MOBX:PIPECommonWarrantsMember 2024-10-01 2024-12-31 0001855467 us-gaap:FairValueInputsLevel2Member MOBX:PIPECommonWarrantsMember 2024-10-01 2024-12-31 0001855467 us-gaap:FairValueInputsLevel3Member MOBX:PIPECommonWarrantsMember 2024-10-01 2024-12-31 0001855467 MOBX:PIPECommonWarrantsMember 2024-10-01 2024-12-31 0001855467 us-gaap:FairValueInputsLevel1Member MOBX:PrivateWarrantsMember 2024-10-01 2024-12-31 0001855467 us-gaap:FairValueInputsLevel2Member MOBX:PrivateWarrantsMember 2024-10-01 2024-12-31 0001855467 us-gaap:FairValueInputsLevel3Member MOBX:PrivateWarrantsMember 2024-10-01 2024-12-31 0001855467 MOBX:PrivateWarrantsMember 2024-10-01 2024-12-31 0001855467 us-gaap:FairValueInputsLevel1Member 2024-10-01 2024-12-31 0001855467 us-gaap:FairValueInputsLevel2Member 2024-10-01 2024-12-31 0001855467 us-gaap:FairValueInputsLevel3Member 2024-10-01 2024-12-31 0001855467 MOBX:EarnoutLiabilityMember 2024-09-30 0001855467 MOBX:LiabilityClassifiedWarrantsMember 2024-09-30 0001855467 MOBX:LiabilityClassifiedWarrantsMember 2024-10-01 2024-12-31 0001855467 MOBX:EarnoutLiabilityMember 2024-12-31 0001855467 MOBX:LiabilityClassifiedWarrantsMember 2024-12-31 0001855467 MOBX:EarnoutLiabilityMember 2023-09-30 0001855467 MOBX:LiabilityClassifiedWarrantsMember 2023-09-30 0001855467 MOBX:PIPEMakeWholeLiabilityMember 2023-09-30 0001855467 MOBX:SAFEsMember 2023-09-30 0001855467 MOBX:LiabilityClassifiedWarrantsMember 2023-10-01 2023-12-31 0001855467 MOBX:SAFEsMember 2023-10-01 2023-12-31 0001855467 MOBX:EarnoutLiabilityMember 2023-12-31 0001855467 MOBX:LiabilityClassifiedWarrantsMember 2023-12-31 0001855467 MOBX:PIPEMakeWholeLiabilityMember 2023-12-31 0001855467 MOBX:SAFEsMember 2023-12-31 0001855467 MOBX:EarnoutLiabilityMember 2024-12-31 0001855467 MOBX:EarnoutLiabilityMember 2024-09-30 0001855467 MOBX:EarnoutLiabilityMember 2024-10-01 2024-12-31 0001855467 MOBX:EarnoutLiabilityMember 2023-10-01 2024-09-30 0001855467 MOBX:PIPEMakeWholeLiabilityMember 2024-12-31 0001855467 MOBX:PIPEMakeWholeLiabilityMember 2024-09-30 0001855467 MOBX:PIPEMakeWholeLiabilityMember 2024-10-01 2024-12-31 0001855467 MOBX:PIPEMakeWholeLiabilityMember 2023-10-01 2024-09-30 0001855467 MOBX:PIPEMakeWholeLiabilityMember srt:MinimumMember 2024-10-01 2024-12-31 0001855467 MOBX:PIPEMakeWholeLiabilityMember srt:MaximumMember 2024-10-01 2024-12-31 0001855467 MOBX:PIPEMakeWholeLiabilityMember srt:MinimumMember 2023-10-01 2024-09-30 0001855467 MOBX:PIPEMakeWholeLiabilityMember srt:MaximumMember 2023-10-01 2024-09-30 0001855467 srt:ScenarioForecastMember srt:MinimumMember 2027-08-31 0001855467 srt:ScenarioForecastMember srt:MaximumMember 2027-08-31 0001855467 2024-10-01 0001855467 MOBX:LeaseMember 2024-12-31 0001855467 MOBX:EMISolutionsMember 2023-12-31 0001855467 MOBX:EMISolutionsMember 2023-10-01 2023-12-31 0001855467 us-gaap:CommonClassBMember 2024-10-01 2024-12-31 0001855467 us-gaap:PrivatePlacementMember 2023-10-01 2023-12-31 0001855467 us-gaap:PrivatePlacementMember 2023-12-31 0001855467 MOBX:PublicWarrantsMember 2024-12-31 0001855467 MOBX:PublicWarrantsMember 2024-09-30 0001855467 MOBX:PrivateWarrantsMember 2024-12-31 0001855467 MOBX:PrivateWarrantsMember 2024-09-30 0001855467 MOBX:PIPEWarrantsMember 2024-12-31 0001855467 MOBX:PIPEWarrantsMember 2024-09-30 0001855467 MOBX:PIPECommonWarrantsMember 2024-12-31 0001855467 MOBX:PIPECommonWarrantsMember 2024-09-30 0001855467 MOBX:OtherWarrantsMember 2024-12-31 0001855467 MOBX:OtherWarrantsMember 2024-09-30 0001855467 us-gaap:CommonStockMember 2023-12-31 0001855467 us-gaap:CommonStockMember us-gaap:InvestorMember 2023-12-31 0001855467 us-gaap:CommonClassAMember 2023-12-31 0001855467 us-gaap:CommonClassAMember MOBX:LegacyMobixMember 2023-12-31 0001855467 MOBX:LegacyMobixMember 2023-10-01 2023-12-31 0001855467 MOBX:TwoThousandsTwentyThreeEquityIncentivePlanMember 2024-12-31 0001855467 us-gaap:RestrictedStockUnitsRSUMember 2023-12-20 2023-12-20 0001855467 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-12-20 0001855467 us-gaap:RestrictedStockUnitsRSUMember 2023-10-01 2023-12-31 0001855467 MOBX:CommonStockWarrantsMember 2024-10-01 2024-12-31 0001855467 MOBX:CommonStockWarrantsMember 2024-12-31 0001855467 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001855467 us-gaap:RestrictedStockUnitsRSUMember 2024-10-01 2024-12-31 0001855467 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001855467 srt:MinimumMember 2023-10-01 2023-12-31 0001855467 srt:MaximumMember 2023-10-01 2023-12-31 0001855467 us-gaap:CostOfSalesMember 2024-10-01 2024-12-31 0001855467 us-gaap:CostOfSalesMember 2023-10-01 2023-12-31 0001855467 us-gaap:ResearchAndDevelopmentExpenseMember 2024-10-01 2024-12-31 0001855467 us-gaap:ResearchAndDevelopmentExpenseMember 2023-10-01 2023-12-31 0001855467 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-10-01 2024-12-31 0001855467 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-10-01 2023-12-31 0001855467 us-gaap:CommonClassAMember 2023-10-01 2023-12-31 0001855467 us-gaap:CommonClassBMember 2023-10-01 2023-12-31 0001855467 MOBX:PublicAndPrivateWarrantsMember 2024-10-01 2024-12-31 0001855467 MOBX:PublicAndPrivateWarrantsMember 2023-10-01 2023-12-31 0001855467 MOBX:PIPECommonWarrantsMember 2024-10-01 2024-12-31 0001855467 MOBX:PIPECommonWarrantsMember 2023-10-01 2023-12-31 0001855467 MOBX:OtherCommonStockWarrantsMember 2024-10-01 2024-12-31 0001855467 MOBX:OtherCommonStockWarrantsMember 2023-10-01 2023-12-31 0001855467 MOBX:EarnoutSharesMember 2024-10-01 2024-12-31 0001855467 MOBX:EarnoutSharesMember 2023-10-01 2023-12-31 0001855467 MOBX:RageEarnoutMember 2024-10-01 2024-12-31 0001855467 MOBX:RageEarnoutMember 2023-10-01 2023-12-31 0001855467 us-gaap:RestrictedStockUnitsRSUMember 2024-10-01 2024-12-31 0001855467 us-gaap:RestrictedStockUnitsRSUMember 2023-10-01 2023-12-31 0001855467 us-gaap:EmployeeStockOptionMember 2024-10-01 2024-12-31 0001855467 us-gaap:EmployeeStockOptionMember 2023-10-01 2023-12-31 0001855467 MOBX:PIPEMakeWholeSharesMember 2024-10-01 2024-12-31 0001855467 MOBX:PIPEMakeWholeSharesMember 2023-10-01 2023-12-31 0001855467 MOBX:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-10-01 2024-12-31 0001855467 MOBX:TwoCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-10-01 2023-12-31 0001855467 MOBX:NoOtherCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-10-01 2024-12-31 0001855467 MOBX:NoOtherCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-10-01 2023-12-31 0001855467 MOBX:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-10-01 2024-12-31 0001855467 MOBX:TwoCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-10-01 2023-12-31 0001855467 country:US 2024-10-01 2024-12-31 0001855467 country:US 2023-10-01 2023-12-31 0001855467 MOBX:OtherMember 2024-10-01 2024-12-31 0001855467 MOBX:OtherMember 2023-10-01 2023-12-31 0001855467 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember 2025-01-01 2025-01-31 0001855467 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember 2025-01-31 0001855467 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember us-gaap:InvestorMember 2025-01-01 2025-01-31 0001855467 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember us-gaap:InvestorMember 2025-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended December 31, 2024

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________ to ______________

 

Commission File Number 001-40621

 

MOBIX LABS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   98-1591717

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

15420 Laguna Canyon Rd., Suite 100

Irvine, California 92618

(Address of principal executive offices and zip code)

 

(949) 808-8888

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, par value $0.00001 per share   MOBX   Nasdaq Capital Market
Redeemable warrants, each warrant exercisable for one share of Class A Common Stock   MOBXW   Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares of the registrant’s Class A Common Stock and Class B Common Stock outstanding as of January 31, 2025 was 34,988,198 and 2,004,901, respectively.

 

 

 

 

 

MOBIX LABS, INC.

 

TABLE OF CONTENTS

 

    Page
     
PART I. FINANCIAL INFORMATION 1
     
Item 1. Financial Statements (unaudited) 1
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 29
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 41
     
Item 4. Controls and Procedures 41
     
PART II. OTHER INFORMATION 44
     
Item 1. Legal Proceedings 44
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44
     
Item 5. Other Information 44
     
Item 6. Exhibits 45
     
  Signatures 46

 

i

 

Cautionary Note Regarding Forward-Looking Statements

 

This quarterly report on Form 10-Q for Mobix Labs, Inc. (the “Company”, “we”, “us” or “our”) contains “forward-looking statements,” as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are statements other than historical information or statements of current condition and relate to future events or our future financial performance. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. In this Quarterly Report on Form 10-Q, forward-looking statements include, but are not limited to, any statements regarding:

 

  our financial and business performance;
  our ability to regain compliance with listing rules of the Nasdaq Stock Market LLC (“Nasdaq”), as well as any decisions that we may make in order to regain compliance;
  our intent to pursue acquisitions of companies and technologies;
  changes in our strategy, future operations, financial position, estimated revenues and losses, forecasts, projected costs, prospects and plans;
  our expectation regarding our ability to continue as a going concern and ability to obtain sufficient liquidity to meet our operating needs and satisfy our obligations;
  the impact of the acquisitions of EMI Solutions, Inc. and RaGE Systems, Inc., and any impact on our business and results of operations;
  the implementation, market acceptance and success of our products and technology in the wireless and connectivity markets and in potential new categories for expansion;
  the demand for our products and the drivers of that demand;
  our opportunities and strategies for growth;
  competition in our industry, the advantages of our products and technology over competing products and technology existing in the market, and competitive factors including with respect to technological capabilities, cost and scalability;
  our ability to scale in a cost-effective manner and maintain and expand our manufacturing and supply chain relationships;
  our expectation that we will incur substantial expenses and continuing losses for the foreseeable future;
  our expectations regarding reliance on a limited number of customers and efforts to diversify our customer base;
  our expectations regarding our ability to obtain and maintain intellectual property protection and not infringe on the rights of others;
  general economic and socio-political conditions and their impact on demand for our technology and on the supply chain on which we rely;
  future capital requirements and sources and uses of cash; and
  the outcome of any known and unknown litigation and regulatory proceedings.

 

These forward-looking statements are based on information available as of the date of this Quarterly Report on Form 10-Q, and current expectations, forecasts, and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include:

 

  the inability to maintain our listing of securities on Nasdaq;
  the inability to meet future capital requirements and the risk that we will be unable to raise additional capital in the future on attractive terms or at all, as well as the dilutive impact that may have on our stockholders;

 

ii

 

  the risk that we are unable to successfully commercialize our products and solutions, or experience significant delays in doing so;
  the risk that we may not be able to generate sufficient income from operations to sustain ourselves;
  the risks concerning our ability to continue as a going concern;
  the risk that we experience difficulties in managing our growth and expanding operations;
  the risk that we may not be able to consummate planned strategic acquisitions, or fully realize anticipated benefits from past or future acquisitions or investments;
  the risk that litigation may be commenced against us;
  the risk that our patent applications may not be approved or may take longer than expected, and we may incur substantial costs in enforcing and protecting our intellectual property;
  our ability to attract new customers and grow our customer base; and
  the risk that the price of our securities may be volatile due to a variety of factors, including changes in the political administration as well as any impact that may have on laws and regulations, changes in the competitive industries in which we operate, variations in performance across competitors, the global supply chain, and macro-economic and social environments affecting our business and changes in our capital structure.

 

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by geopolitical tensions, including the further escalation of war between Russia and Ukraine or the conflict pertaining to the Middle East, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. However, we encourage you to review our risk factors as set forth in our annual report on Form 10-K for our fiscal year ended September 30, 2024, filed with the Securities and Exchange Commission on December 26, 2024.

 

iii

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Mobix Labs, Inc.

Unaudited Condensed Consolidated Financial Statements

December 31, 2024 and 2023

 

Condensed Consolidated Balance Sheets as of December 31, 2024 and September 30, 2024 (unaudited)   2
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three months ended December 31, 2024 and 2023 (unaudited)   3
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three months ended December 31, 2024 and 2023 (unaudited)   4
Condensed Consolidated Statements of Cash Flows for the three months ended December 31, 2024 and 2023 (unaudited)   5
Notes to Condensed Consolidated Financial Statements (unaudited)   6

 

1

 

MOBIX LABS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited, in thousands, except share and per share amounts)

 

    December 31,     September 30,  
    2024     2024  
ASSETS                
Current assets                
Cash   $ 405     $ 266  
Accounts receivable, net     1,876       2,813  
Inventory     1,242       1,725  
Prepaid expenses and other current assets     301       467  
Total current assets     3,824       5,271  
                 
Property and equipment, net     1,070       1,177  
Intangible assets, net     14,740       15,211  
Goodwill     16,066       16,066  
Operating lease right-of-use assets     1,084       1,022  
Other assets     487       341  
Total assets   $ 37,271     $ 39,088  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)                
Current liabilities                
Accounts payable   $ 10,944     $ 10,833  
Accrued expenses and other current liabilities     11,894       10,325  
Deferred purchase consideration     2,272       2,380  
Notes payable, current     723       398  
Notes payable – related parties, current     2,023       1,743  
Operating lease liabilities, current     583       428  
Total current liabilities     28,439       26,107  
                 
Notes payable, noncurrent     71       200  
Notes payable – related parties, noncurrent     802       1,082  
Earnout liability     3,620       1,680  
Deferred tax liability     315       320  
Operating lease liabilities, noncurrent     901       1,024  
Other noncurrent liabilities     6,162       3,145  
Total liabilities     40,310       33,558  
                 
Commitments and contingencies (Note 13)     -       -  
                 
Stockholders’ equity (deficit)                
Class A common stock, $0.00001 par value, 285,000,000 shares authorized; 34,652,774 and 32,824,230 shares issued and outstanding at December 31, 2024 and September 30, 2024, respectively            
Class B common stock, $0.00001 par value, 5,000,000 shares authorized; 2,004,901 and 2,129,901 shares issued and outstanding at December 31, 2024 and September 30, 2024, respectively            
Additional paid-in capital     121,257       109,987  
Accumulated deficit     (124,296 )     (104,457 )
Total stockholders’ equity (deficit)     (3,039 )     5,530  
Total liabilities and stockholders’ equity (deficit)   $ 37,271     $ 39,088  

 

See accompanying notes to condensed consolidated financial statements.

 

2

 

MOBIX LABS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME (LOSS)

(unaudited, in thousands, except share and per share amounts)

 

    2024     2023  
   

Three months ended

December 31,

 
    2024     2023  
             
Net revenue   $ 3,169     $ 285  
Cost of revenue     1,482       329  
Gross profit     1,687       (44 )
                 
Operating expenses:                
Research and development     611       1,562  
Selling, general and administrative     15,706       15,663  
Loss from operations     (14,630 )     (17,269 )
                 
Interest expense     211       857  
Change in fair value of earnout liability     1,940       (24,764 )
Change in fair value of warrants     2,658       60  
Change in fair value of PIPE make-whole liability           2,904  
Merger-related transaction costs expensed           4,009  
Other non-operating losses, net     402       10  
Loss before income taxes     (19,841 )     (345 )
Provision (benefit) for income taxes     (2 )     (1,280 )
Net income (loss) and comprehensive income (loss)   $ (19,839 )   $ 935  
                 
Net income (loss) per share of Class A and Class B Common Stock:                
Basic   $ (0.52 )   $ 0.04  
Diluted   $ (0.52 )   $ 0.04  
Weighted-average common shares outstanding:                
Basic     38,425,566       18,617,656  
Diluted     38,425,566       23,316,071  

 

See accompanying notes to condensed consolidated financial statements.

 

3

 

MOBIX LABS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(unaudited, in thousands, except share and per share amounts)

 

    Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Capital     Deficit     (Deficit)  
    Founders
Redeemable
Convertible
Preferred Stock
    Series A
Redeemable
Convertible
Preferred Stock
    Contingently
Redeemable
Common Stock
    Legacy
Common Stock
    Class A
Common Stock
    Class B
Common Stock
    Additional
Paid-in
    Accumulated     Total
Stockholders’
Equity
 
    Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Capital     Deficit     (Deficit)  
Balance at September 30, 2024         $           $           $           $       32,824,230     $       2,129,901     $     $ 109,987     $ (104,457 )   $ 5,530  
                                                                                                                         
Issuance of common stock                                                     561,739                         640             640  
Conversion of Class B common stock to Class A common stock                                                     125,000             (125,000 )                        
Conversion of notes payable to Class A common stock                                                     631,805                         828             828  
Issuance of common stock upon vesting of RSUs                                                     510,000                                      
Stock-based compensation                                                                             9,802             9,802  
Net loss                                                                                   (19,839 )     (19,839 )
                                                                                                                         
Balance at December 31, 2024         $           $           $           $       34,652,774     $       2,004,901     $     $ 121,257     $ (124,296 )   $ (3,039 )
                                                                                                                         
Balance at September 30, 2023     588,235     $       1,666,666     $ 2,300           $       16,692,175     $           $           $     $ 78,421     $ (83,762 )   $ (5,341 )
Issuance of common stock                                         482,171                                       3,286             3,286  
Issuance of contingently redeemable common stock for acquisition of EMI Solutions, Inc.                             964,912       8,856                                                        
Lapse of redemption feature on common stock                             (964,912 )     (8,856 )     964,912                                     8,856             8,856  
Issuance of warrants in connection with notes payable                                                                             107             107  
Reverse recapitalization transactions, net (Note 3)     (588,235 )           (1,666,666 )     (2,300 )                 (18,139,258 )           22,901,838             2,254,901             (16,182 )           (16,182 )
Issuance of common stock upon exercise of stock options                                                     168,235                                      
Issuance of common stock upon exercise of warrants                                                     369,671                                      
Issuance of common stock upon vesting of RSUs                                                     104,748                                      
Stock-based compensation                                                                             12,705             12,705  
Net income                                                                                   935       935  
                                                                                                                         
Balance at December 31, 2023         $           $           $           $       23,544,492     $       2,254,901     $     $ 87,193     $ (82,827 )   $ 4,366  

 

See accompanying notes to condensed consolidated financial statements.

 

4

 

MOBIX LABS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited, in thousands)

 

    2024     2023  
   

Three months ended

December 31,

 
    2024     2023  
Operating activities                
Net income (loss)   $ (19,839 )   $ 935  
Adjustments to reconcile net income (loss) to net cash used in operating activities:                
Depreciation     123       113  
Amortization of intangible assets     471       237  
Issuance of warrants in connection with notes payable, charged to interest expense           729  
Change in fair value of earnout liability     1,940       (24,764 )
Change in fair value of warrants     2,658       60  
Change in fair value of PIPE make-whole liability           2,904  
Merger-related transaction costs expensed           4,009  
Stock-based compensation     9,802       12,705  
Deferred income taxes     (5 )     (1,280 )
Other non-cash items     531       (11 )
Changes in operating assets and liabilities, net of acquisition of business:                
Accounts receivable     937       136  
Inventory     483       52  
Prepaid expenses and other assets     20       27  
Accounts payable     95       525  
Accrued expenses and other current liabilities     1,854       27  
Net cash used in operating activities     (930 )     (3,596 )
                 
Investing activities                
Acquisition of EMI Solutions, Inc., net of cash acquired           (110 )
Acquisition of property and equipment           (5 )
Net cash used in investing activities           (115 )
                 
Financing activities                
Proceeds from issuance of common stock     600       3,286  
Proceeds from issuance of notes payable     675       246  
Proceeds from issuance of convertible notes           200  
Principal payments on notes payable     (32 )     (18 )
Principal payments on notes payable – related parties           (344 )
Deferred consideration paid for acquisition of business     (174 )      
Proceeds from the Merger and PIPE           21,014  
Merger-related transaction costs paid           (5,966 )
Net cash provided by financing activities     1,069       18,418  
                 
Net increase in cash     139       14,707  
Cash, beginning of period     266       89  
Cash, end of period   $ 405     $ 14,796  
                 
Supplemental cash flow information                
Cash paid for interest   $ 64     $ 80  
Cash paid for income taxes            
                 
Non-cash investing and financing activities:                
Conversion of notes payable to common stock   $ 545     $  
Unpaid Merger-related transaction costs           2,504  
Contingently redeemable convertible stock issued for acquisition of EMI Solutions, Inc.           8,856  
Unpaid purchase consideration for acquisition of businesses           1,886  
Conversion of SAFEs to common stock           1,522  
Issuance of warrants in connection with notes payable, recorded as debt discount           107  

 

See accompanying notes to condensed consolidated financial statements.

 

5

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited, in thousands, except share and per share amounts)

 

Note 1 — Company Information

 

Mobix Labs, Inc. (“Mobix Labs” or the “Company”), a Delaware corporation based in Irvine, California, designs, develops and sells components and systems for advanced wireless and wired connectivity, radio frequency (“RF”), switching and electromagnetic interference (“EMI”) filtering technologies used in the consumer commercial, industrial, automotive, medical, aerospace, defense and other markets. The Company’s wireless systems solutions include products for advanced RF and millimeter wave (“mmWave”) 5G communications, mmWave imaging, software defined radio and custom RF integrated circuits targeting the commercial, industrial, and defense and aerospace sectors. The Company’s interconnect products, including EMI filter inserts and filtered and non-filtered connectors, are designed for and currently used in aerospace, military, defense and medical applications. The Company’s True Xero active optical cables (“AOCs”) are designed to meet customer needs for high-quality active optical cable solutions at an affordable price. These technologies are designed for large and rapidly growing markets where there is increasing demand for higher performance communication and filtering systems which utilize an expanding mix of both wireless and connectivity technologies.

 

On December 21, 2023, (the “Closing Date”), Chavant Capital Acquisition Corp. (“Chavant”) consummated the merger pursuant to the Business Combination Agreement, dated November 15, 2022 (as amended, supplemented or otherwise modified, the “Business Combination Agreement”), by and among Chavant, CLAY Merger Sub II, Inc., a Delaware corporation and newly formed, wholly-owned direct subsidiary of Chavant (“Merger Sub”), and Mobix Labs, Inc. (“Legacy Mobix”), a Delaware corporation, pursuant to which, among other things, Merger Sub merged with and into Legacy Mobix, with Legacy Mobix surviving the merger as a wholly-owned direct subsidiary of Chavant (together with the other transactions related thereto, the “Merger”). In connection with the consummation of the Merger (the “Closing”), Chavant changed its name from “Chavant Capital Acquisition Corp.” to “Mobix Labs, Inc.” and Legacy Mobix changed its name from “Mobix Labs, Inc.” to “Mobix Labs Operations, Inc.” As a result of the Merger, the Company raised gross proceeds of $21,014, including the contribution of $1,264 of cash held in Chavant’s trust account and the $19,750 private investment in public equity (“PIPE”) at $10.00 per share of Chavant’s Class A Common Stock. The common stock and public warrants of the combined company began trading on The Nasdaq Stock Market LLC under the symbols “MOBX” and “MOBXW,” respectively, on December 22, 2023.

 

Throughout the notes to the condensed consolidated financial statements, unless otherwise noted or otherwise suggested by context, the “Company” refers to Legacy Mobix prior to the consummation of the Merger, and to the Company after the consummation of the Merger.

 

Going Concern

 

The condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. Since inception, the Company has incurred operating losses and negative cash flows from operations, primarily as a result of its ongoing investment in product development and other operating expenses. For the three months ended December 31, 2024 and 2023, the Company incurred losses from operations of $14,630 and $17,269, respectively, and as of December 31, 2024, the Company had an accumulated deficit of $124,296. The Company has historically financed its operations through the issuance and sale of equity securities and the issuance of debt. The Company expects to continue to incur operating losses and negative cash flows from operations for the foreseeable future and will need to raise additional debt or equity financing to fund its operations and satisfy its obligations. Management believes that there is substantial doubt concerning the Company’s ability to continue as a going concern as the Company currently does not have adequate liquidity to meet its operating needs and satisfy its obligations beyond the next approximately ninety days.

 

While the Company will seek to raise additional capital, there can be no assurance the necessary financing will be available on terms acceptable to the Company, or at all. If the Company raises funds by issuing equity securities, dilution to existing stockholders may result. Any equity securities issued may also provide for rights, preferences or privileges senior to those of holders of common stock. If the Company raises funds by issuing debt securities, such debt securities would have rights, preferences and privileges senior to those of preferred and common stockholders. The terms of debt securities or borrowings may impose significant restrictions on the Company’s operations. The capital markets have in the past, and may in the future, experience periods of volatility that could impact the availability and cost of equity and debt financing. In addition, recent and potential future increases in federal funds rates set by the Federal Reserve, which serve as a benchmark for rates on borrowing, could adversely impact the cost or availability of debt financing.

 

6

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

If the Company is unable to obtain additional financing, or if such transactions are successfully completed but do not provide adequate financing, the Company may be required to reduce its operating expenditures, which could adversely affect its business prospects, or the Company may be unable to continue operations. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.

 

Note 2 — Summary of Significant Accounting Policies

 

Basis of Presentation

 

The Merger was accounted for as a reverse recapitalization of the Company because Legacy Mobix has been determined to be the accounting acquirer under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805 – Business Combinations. Under this method of accounting, Chavant is treated as the “acquired” company for financial reporting purposes. This determination was primarily based on holders of Legacy Mobix capital stock comprising a relative majority of the voting power of the Company upon consummation of the Merger and having the ability to nominate the majority of the governing body of the Company, Legacy Mobix senior management comprising the senior management of the Company, and Legacy Mobix operations comprising the ongoing operations of the Company. Accordingly, for accounting purposes, the financial statements of the Company represent a continuation of the financial statements of Legacy Mobix with the Merger being treated as the equivalent of Legacy Mobix issuing shares for the net assets of Chavant, accompanied by a recapitalization. The net assets of Chavant were recognized as of the Closing at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Merger are presented as those of Legacy Mobix and the accumulated deficit of Legacy Mobix has been carried forward after Closing. All issued and outstanding securities of Chavant upon Closing were treated as issuances of securities of the Company upon the consummation of the Merger.

 

The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and include the accounts of Mobix Labs, Inc. and its subsidiaries. The Company’s fiscal year ends on September 30. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended September 30, 2024 and the related notes which provide a more complete discussion of the Company’s accounting policies and certain other information. The September 30, 2024 condensed consolidated balance sheet was derived from the Company’s audited financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s condensed consolidated financial position as of December 31, 2024 and its condensed consolidated results of operations and cash flows for the three months ended December 31, 2024 and 2023. The condensed consolidated results of operations for the three months ended December 31, 2024 are not necessarily indicative of the results to be expected for the fiscal year ending September 30, 2025 or for any other future annual or interim period.

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

 

7

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Use of Estimates

 

The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of certain assets and liabilities; the reported amounts of net revenue and expenses for the periods covered and certain amounts disclosed in the notes to the condensed consolidated financial statements. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:

 

  valuation of stock-based compensation awards;
  valuation of common stock for periods prior to the Merger;
  impairment assessments of goodwill and long-lived assets;
  measurement of liabilities carried at fair value, including the earnout liability, the PIPE make-whole liability and liability-classified warrants;
  purchase price allocations and valuations of net assets acquired in business combinations; and,
  provisions for income taxes and related valuation allowances and tax uncertainties.

 

Cash

 

As of December 31, 2024 and September 30, 2024, the Company’s cash balance consisted of demand deposits held at large financial institutions. The Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company had no cash equivalents as of December 31, 2024 or September 30, 2024. The amount of deposits maintained at any financial institution may exceed federally insured limits. The Company places its cash with high credit quality financial institutions and has not experienced any losses on its deposits of cash.

 

Accounts Receivable, net

 

Accounts receivable are recorded at the invoiced amount and do not bear interest. For trade accounts receivable from customers, the Company performs ongoing credit evaluations of its customers and maintains an allowance for expected credit losses. The allowance for expected credit losses represents the Company’s best estimate based on current and historical information, and reasonable and supportable forecasts of future events and circumstances. Accounts receivable deemed uncollectible are charged against the allowance for expected credit losses when identified. The allowance for expected credit losses as of December 31, 2024 and September 30, 2024 and bad debt expense for the three months ended December 31, 2024 and 2023 were not material.

 

Inventory

 

Inventory is stated at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory costs consist of purchased materials, manufacturing labor, outside manufacturing costs, inbound freight and receiving costs, and capitalized overhead. The Company records an inventory reserve for losses associated with excess and obsolete items, based on available information and the Company’s current expectations of future demand, product obsolescence and market conditions. Any provision for excess and obsolete inventory is charged to cost of revenue and is a permanent reduction of the carrying value of inventory. The reserve for excess and obsolete inventory as of December 31, 2024 and September 30, 2024 and write-downs of obsolete inventory for the three months ended December 31, 2024 and 2023 were not material.

 

Intangible Assets, net

 

The Company’s intangible assets principally consist of acquired developed technology and customer relationships and have finite lives ranging from one to fifteen years. The Company amortizes intangible assets over their useful lives on a straight-line basis, which the Company believes approximates the pattern in which the economic benefits of the intangible assets are expected to be utilized. To the extent that an acquired developed technology is incorporated in, or used to produce, a product the Company currently produces and sells, the related amortization expense is included in cost of revenue in the condensed consolidated statements of operations and comprehensive income (loss). Amortization expense on other acquisition-related intangible assets is included in operating expenses.

 

8

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Impairment of Long-Lived Assets

 

The Company reviews its long-lived assets, consisting of property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company regularly reviews its operating performance for indicators of impairment. Factors considered important that could trigger an impairment review include a significant underperformance relative to expected historical or projected future operating results, or a significant change in the manner of the use of the assets. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is determined by comparing the forecasted undiscounted cash flows attributable to such assets including any cash flows upon their eventual disposition to their carrying value. If the carrying value of the assets exceeds the forecasted undiscounted cash flows, then the assets are written down to their fair value. The Company did not record any impairment losses on long-lived assets for the three months ended December 31, 2024 and 2023.

 

Goodwill

 

Goodwill represents the excess of the fair value of purchase consideration of an acquired business over the fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at a reporting unit level on an annual basis on July 31, or more frequently if circumstances change or an event occurs that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company did not record any goodwill impairment losses for the three months ended December 31, 2024 and 2023.

 

Business Combinations

 

The Company allocates the purchase price of an acquisition to the tangible assets acquired, liabilities assumed, and intangible assets acquired, based on their estimated fair values. The excess of the purchase price over the fair values of the net assets acquired is recorded as goodwill.

 

Accounting for business combinations requires that management make significant estimates and assumptions to determine the fair value of assets acquired and liabilities assumed at the acquisition date. Although management believes the assumptions and estimates to be reasonable and appropriate, they are inherently uncertain. Critical estimates in valuing certain acquired assets may include, but are not limited to, expected future cash flows including revenue growth rate assumptions from product sales, customer contracts and acquired technologies, expected costs to develop acquired technology into commercially viable products, estimated cash flows from the projects when completed, including assumptions associated with the technology migration curve and expected selling, general and administrative costs. The discount rates used to discount expected future cash flows to present value are typically derived from a weighted-average cost of capital analysis and are adjusted to reflect inherent risks. Unanticipated events and circumstances may occur that could affect either the accuracy or validity of such assumptions, estimates or actual results.

 

Fair Value Measurements

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tiered hierarchy for inputs used in measuring fair value that emphasizes the use of observable inputs over the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are market participant assumptions based on market data obtained from sources independent of the Company. Unobservable inputs are the Company’s own assumptions of what market participants would use in pricing an asset or liability based on the best information available in the circumstances. The financial and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.

 

9

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

As a basis for considering such assumptions, a three-tier hierarchy is used in management’s determination of fair value based on the reliability and observability of inputs as follows:

 

Level 1 — Observable inputs that include quoted prices in active markets for identical assets or liabilities.

 

Level 2 — Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 — Unobservable pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations.

 

The Company’s non-financial assets, including property and equipment, intangible assets and goodwill, are measured at estimated fair value on a nonrecurring basis. These assets are adjusted to fair value only when an impairment is recognized, or in the event an asset is held for sale.

 

Net Income (Loss) Per Share

 

Basic and diluted net income (loss) per share attributable to common stockholders is presented using the two-class method required for participating securities. Under the two-class method, net income (loss) is attributed to the Class A and Class B common stock and other participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is computed using the weighted-average number of shares and the effect of potentially dilutive securities outstanding during the period. For a period in which the Company reports a net loss, diluted net loss per share is similar to basic net loss per share because potentially dilutive common shares are not assumed to have been issued if their effect is antidilutive. See Note 18, Net Income (Loss) Per Share.

 

Comprehensive Income (Loss)

 

Comprehensive income (loss) includes the Company’s net income (loss) as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders. There were no differences between the Company’s net income (loss) and comprehensive income (loss) for the three months ended December 31, 2024 and 2023.

 

Revenue Recognition

 

The Company accounts for revenue from contracts with customers in accordance with ASC 606, Revenue from Contracts with Customers. The Company derives its revenues primarily from product sales to equipment manufacturers. The Company recognizes product revenue when it satisfies performance obligations under the terms of its contracts and upon transfer of control when title transfers (either upon shipment to or receipt by the customer, as determined by the terms of the contract) net of accruals for estimated sales returns and allowances. Such sales returns and allowances were not material for the three months ended December 31, 2024 and 2023. The Company does not have material variable consideration, and the Company’s revenue arrangements do not contain significant financing components. Payment terms are principally net 30 days to net 45 days.

 

The Company generally offers a limited warranty to customers covering a period of twelve months which obligates the Company to repair or replace defective products. The warranty is not sold separately and does not represent a separate performance obligation. Therefore, the Company accounts for such warranties under ASC Topic 460, Guarantees, and the estimated costs of warranty claims are accrued as cost of revenue in the period the related revenue is recorded. The Company accrues for warranty and indemnification issues if a loss is probable and can be reasonably estimated. Warranty and indemnification expenses have historically been insignificant.

 

The Company includes shipping and handling fees billed to customers as part of net revenue. The Company includes shipping and handling costs associated with outbound freight in cost of revenue. Sales and other taxes the Company collects, if any, are excluded from revenue.

 

There were no contract assets recorded on the condensed consolidated balance sheets as of December 31, 2024 or September 30, 2024. In some instances, the Company receives a partial payment of the sales price from the customer at the time an order is placed. Any such prepayments are recorded as a liability included in “Accrued expenses and other current liabilities” on the condensed consolidated balance sheets and are recognized in net revenue when the Company satisfies the related performance obligations, typically as products are shipped. All incremental customer contract acquisition costs are expensed as incurred as the amortization period of the asset that the Company otherwise would have recognized is one year or less in duration.

 

10

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Accounting Pronouncements Recently Adopted

 

None.

 

Recently Issued Accounting Pronouncements Not Yet Adopted

 

The Company is an “emerging growth company,” as defined in the Securities Act. Under the Jumpstart Our Business Startups Act of 2012, an emerging growth company has the option to adopt new or revised accounting guidance either (i) within the same periods as otherwise applicable to public business entities, or (ii) within the same time periods as non-public business entities, including early adoption when permissible. With the exception of accounting guidance the Company elected to early adopt, when permissible, the Company has elected to adopt new or revised accounting guidance within the same time periods as non-public business entities.

 

In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 expands segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The disclosures required under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for the Company’s fiscal year beginning October 1, 2024 and for interim periods within the Company’s fiscal year beginning October 1, 2025, with early adoption permitted. The Company does not expect adoption of ASU 2023-07 will have a material impact on its financial position or results of operations.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The ASU is effective for the Company’s fiscal year beginning October 1, 2025. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company does not expect adoption of ASU 2023-09 will have a material impact on its financial position or results of operations.

 

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) (“ASU 2024-03”). ASU 2024-03 requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The ASU is effective for the Company’s fiscal year beginning October 1, 2027, and for interim periods within the Company’s fiscal year beginning October 1, 2028, with early adoption permitted. The Company is currently evaluating the ASU to determine the impact it will have on the Company’s financial statements and related disclosures.

 

Note 3 — Reverse Recapitalization

 

As discussed in Note 1, Company Information, the Closing of the Merger occurred on December 21, 2023. In the Merger, as provided for in the Business Combination Agreement:

 

  All of Legacy Mobix’s 18,139,258 issued and outstanding shares of common stock were cancelled and converted into the same number of shares of the Company’s Class A Common Stock;
  All of Legacy Mobix’s Founders Redeemable Convertible Preferred Stock and Series A Redeemable Convertible Preferred Stock, totaling 2,254,901 shares, was converted into the same number of shares of the Company’s Class B Common Stock;
  All of Legacy Mobix’s convertible notes were converted into shares of Legacy Mobix common stock immediately prior to Closing and pursuant to their terms, totaling 30,045 shares, which were then cancelled and converted into the same number of shares of the Company’s Class A Common Stock;
  All of Legacy Mobix’s SAFEs were converted into 150,953 shares of the Company’s Class A Common Stock;
  All of Legacy Mobix’s stock options and warrants were assumed by the Company and converted into the same number of stock options or warrants to purchase shares of the Company’s Class A Common Stock, with no change to their exercise prices, vesting conditions or other terms; and
  All of Legacy Mobix’s restricted stock units (“RSUs”) were assumed by the Company and converted into an RSU covering the same number of shares of the Company’s Class A Common Stock.

 

11

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

The other related events that occurred in connection with the Closing include the following:

 

  The Company entered into the PIPE Subscription Agreements, as described below;
  The Company entered into the Sponsor PIPE Subscription Agreement, Sponsor Warrant and Sponsor Letter Agreement, as described below;
  The Company entered into a non-redemption agreement with a stockholder, as described below;
  The Company entered into an amendment to its Business Combination Marketing Agreement, as described below;
  The Company assumed the 6,000,000 public warrants (“Public Warrants”) and 3,400,000 private placement warrants (“Private Warrants”) originally issued by Chavant in 2021 in connection with its initial public offering, as described in Note 16, Warrants;
  The Company adopted the 2023 Employee Stock Purchase Plan and the 2023 Equity Incentive Plan, as described in Note 17, Stock-Based Compensation;
  The Company adopted an amended and restated certificate of incorporation and amended and restated bylaws; and
  The Company entered into indemnification agreements with each of its directors and officers.

 

PIPE Subscription Agreements

 

In connection with the Merger, Chavant entered into the PIPE Subscription Agreements with certain accredited investors and pursuant to which the investors agreed to purchase an aggregate of 1,975,000 shares of Class A Common Stock of Chavant at a price of $10.00 per share for an aggregate amount of $19,750 in cash. The number of shares purchased by the PIPE investors was initially subject to adjustment. See “Make-Whole Shares,” below.

 

The PIPE investors also received warrants to purchase 1,950,000 shares of Class A Common Stock at an exercise price of $0.01 per share, of which warrants to purchase 200,000 shares are immediately exercisable and warrants to purchase 1,750,000 shares are exercisable upon obtaining stockholder approval, which the Company obtained on January 3, 2025.

 

Sponsor PIPE Subscription Agreements, Sponsor Warrant and Sponsor Letter Agreement

 

On December 19, 2023, Chavant entered into the Sponsor PIPE Subscription Agreement with the Sponsor pursuant to which the Sponsor agreed to purchase, in a private placement that closed substantially concurrently with the Closing, 199,737 shares of Class A Common Stock at a price of $10.00 per share. The aggregate purchase price of $1,997 was paid through the forgiveness of certain obligations of Chavant. The number of shares purchased by the Sponsor was initially subject to adjustment. See “Make-Whole Shares,” below.

 

In connection with the execution of the Sponsor PIPE Subscription Agreement, Legacy Mobix Labs issued to the Sponsor a warrant to purchase 272,454 shares of Legacy Mobix Labs Stock at an exercise price of $0.01 per share, exercisable upon the closing of the Sponsor PIPE Subscription Agreement (the “Sponsor Warrant”). The Sponsor Warrant was exercised at the closing of the Sponsor PIPE Subscription Agreement and, following net settlement into 272,182 shares of Legacy Mobix Labs Stock, converted into 272,182 shares of Class A Common Stock of the Company in connection with the Closing.

 

On December 20, 2023, Chavant also entered into a Sponsor Letter Agreement with the Sponsor pursuant to which, as consideration for the 199,737 shares issued pursuant to the Sponsor PIPE Subscription Agreement described above, the Sponsor agreed to forgive approximately $1,997 of aggregate outstanding obligations of Chavant. In addition, the Sponsor agreed to forfeit 658,631 Founder Shares and 400,000 Private Warrants that it held, in each case upon the Closing.

 

12

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Non-Redemption Agreement

 

On December 20, 2023, Chavant and Mobix Labs entered into a non-redemption agreement with a stockholder of Chavant, pursuant to which the stockholder agreed to withdraw its redemption of 73,706 ordinary shares of Chavant (“Ordinary Shares”) prior to the Merger. In consideration therefor, Mobix Labs issued the stockholder a warrant to purchase 202,692 shares of Legacy Mobix common stock at an exercise price of $0.01 per share, exercisable upon the Closing. The warrant was exercised at the Closing and, following net settlement into 202,489 shares of Legacy Mobix Common Stock, converted into 202,489 shares of Class A Common Stock of the Company in connection with the Closing.

 

Amendment to Business Combination Marketing Agreement

 

On December 21, 2023, Chavant entered into an amendment to the Business Combination Marketing Agreement, dated as of July 19, 2021 between Chavant and certain advisors wherein the parties agreed to resolve their differences with respect to marketing fees contemplated by the agreement and the advisors agreed to receive, in lieu of any cash payment of fees or reimbursement of expenses, an aggregate of 280,000 shares of Class A Common Stock.

 

Earnout Shares

 

In addition to the consideration paid at Closing, certain Legacy Mobix stockholders and certain holders of Legacy Mobix stock options (the “Earnout Recipients”) will be entitled to receive an additional aggregate 3,500,000 shares of Class A Common Stock issuable as earnout shares (the “Earnout Shares”) based on the achievement of trading price targets following the Closing and subject to the terms provided in the Business Combination Agreement. The Earnout Shares have a seven-year “Earnout Period,” commencing on the date that is the one year anniversary of the Closing, pursuant to which up to 1,750,000 shares of Class A Common Stock will be distributed to the Earnout Recipients if the volume-weighted average price (“VWAP”) of the Class A Common Stock exceeds $12.50 for any twenty trading days within a period of thirty consecutive trading days during the Earnout Period and an additional 1,750,000 shares of Class A Common Stock will be distributed to the Earnout Recipients if the VWAP of the Class A Common Stock exceeds $15.00 for any twenty trading days within a period of thirty consecutive trading days during the Earnout Period.

 

The Earnout Shares are accounted for as liability-classified instruments because the events that determine the number of Earnout Shares to which the Earnout Recipients will be entitled include events that are not solely indexed to the Company’s common stock. At the time of Closing, the Company estimated the aggregate fair value of its liability for the Earnout Shares using a Monte Carlo simulation model and recorded a liability of $33,559. As of December 31, 2024, none of the conditions for the issuance of any Earnout Shares had been achieved and the Company adjusted the carrying amount of the liability to its estimated fair value of $3,620. As a result of changes in the estimated fair value of the liability, the Company recognized non-cash gains (losses) of $(1,940) and $24,764, respectively, for the three months ended December 31, 2024 and 2023, which are included in “Change in fair value of earnout liability” in the condensed consolidated statements of operations and comprehensive income (loss).

 

Make-Whole Shares

 

Pursuant to the PIPE Subscription Agreements, the Sponsor PIPE Subscription Agreement and the Amendment to Business Combination Marketing Agreement described above, Chavant agreed to issue additional shares of its Class A Common Stock (the “Make-Whole Shares”) to the PIPE Investors, the Sponsor and certain advisors with respect to 2,454,737 shares of the Company’s Class A Common Stock in the event that the VWAP per share of the Class A Common Stock during a specified adjustment period is less than $10.00 per share. The specified adjustment period ended on August 30, 2024 and the Company issued 1,052,029 shares of its Class A Common Stock in settlement of the liability for the Make-Whole Shares.

 

The Company accounted for the Make-Whole Shares as liability-classified instruments because the events that determined the number of Make-Whole Shares issuable included events that were not solely indexed to the Company’s common stock. At the time of Closing, the Company estimated the aggregate fair value of its liability for the Make-Whole Shares using a Monte Carlo simulation model and recorded a liability of $2,071. As a result of subsequent changes in the fair value of the liability, the Company recorded a non-cash loss of $2,904 for the three months ended December 31, 2023, which is included in “Change in fair value of PIPE make-whole liability” in the condensed consolidated statements of operations and comprehensive income (loss).

 

13

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

See Note 11, Fair Value Measurements, for additional information on the Company’s measurements with respect to the financial instruments issued in connection with the foregoing agreements.

 

Legacy Mobix incurred $6,363 of transaction costs in connection with the Merger, which was determined to be a capital-raising transaction for Legacy Mobix. The Company allocated this amount between the equity-classified instruments and liability-classified instruments, based on their relative fair values, and during the three months ended December 31, 2023, the Company recorded the $2,354 of costs associated with equity-classified instruments as a reduction of additional paid-in capital and charged the remaining $4,009 of costs associated with liability-classified instruments to expense. The Company also recognized a liability for unpaid transaction costs of Chavant totaling $3,090, which the Company recorded as a reduction of the proceeds of the Merger at the time of the Closing.

 

The following tables reconcile elements of the Merger to the Company’s condensed consolidated financial statements, and should be read in conjunction with the footnotes referenced above:

 Schedule of Condensed Consolidated Financial Statements

    Shares  
Chavant public shares, net of redemptions     111,005  
Chavant founder shares, net of shares forfeited     1,341,369  
PIPE investors’ shares     1,975,000  
Settlement of PIPE warrant     199,800  
Sponsor PIPE subscription     199,737  
Settlement of Sponsor Warrant     272,182  
Settlement of warrant to non-redeeming shareholder     202,489  
Amendment to Business Combination Marketing Agreement     280,000  
Total Chavant shares outstanding immediately prior to the Merger     4,581,582  
         
Legacy Mobix rollover shares     18,139,258  
Conversion of Legacy Mobix convertible notes     30,045  
Conversion of Legacy Mobix SAFEs     150,953  
Total number of Class A common shares issued in the Merger     22,901,838  
         
Closing proceeds:        
Proceeds from Chavant trust fund   $ 1,264  
Proceeds from PIPE investment     19,750  
         
Closing disbursements:        
Legacy Mobix Merger-related transaction costs     (3,747 )
Chavant Merger-related transaction costs     (2,219 )
Net cash proceeds from the Merger at Closing     15,048  
         
Legacy Mobix Merger-related transaction costs paid prior to closing     (983 )
Net cash proceeds     14,065  
         
Non-cash activity:        
Conversion of Legacy Mobix convertible notes to Class A Common Stock     206  
Conversion of Legacy Mobix SAFEs to Class A Common Stock     1,522  
Conversion of Legacy Mobix redeemable convertible preferred stock to Class B Common Stock     2,300  
Unpaid Merger-related transaction costs assumed from Chavant     (871 )
Unpaid Merger-related transaction costs of Legacy Mobix     (1,633 )
Merger-related transaction costs expensed     4,009  
         
Liability-classified instruments:        
Fair value of earnout liability     (33,559 )
Fair value of PIPE make-whole liability     (2,071 )
Fair value of Private Warrants     (150 )
Net equity impact of the Merger   $ (16,182 )

 

14

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Note 4 — Acquisitions

 

The Company acquired EMI Solutions, Inc. (“EMI Solutions”) in December 2023 and RaGE Systems, Inc. (“RaGE Systems”) in May 2024. The Company accounted for each of the acquisitions as a business combination. The following table summarizes the amount of the aggregate purchase consideration and the allocation to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values.

 Schedule of Purchase Consideration and Allocation

    EMI Solutions     RaGE Systems  
             
Purchase consideration:                
Contingently redeemable common stock   $ 8,856     $  
Class A Common Stock           7,682  
Cash consideration (at present value)     2,041       1,836  
Total Purchase Consideration   $ 10,897     $ 9,518  
Allocation:                
Cash   $ 45     $ 420  
Accounts receivable     387       558  
Inventory     155       1,146  
Other current assets     7       5  
Property and equipment     107       275  
Intangible asset—customer relationships     4,500       7,400  
Intangible asset—developed technology           300  
Intangible asset—backlog     300        
Intangible asset—trade name     100       200  
Goodwill     6,841       4,008  
Operating lease right-of-use asset           192  
Other assets     30       57  
Accounts payable     (228 )     (1,647 )
Accrued expenses     (263 )     (1,622 )
Operating lease liability           (192 )
Deferred tax liability     (1,084 )     (1,582 )
    $ 10,897     $ 9,518  

 

EMI Solutions, Inc.

 

On December 18, 2023, the Company completed the acquisition of EMI Solutions when the Company acquired all of the issued and outstanding common shares of EMI Solutions, which is accounted for as a business combination. EMI Solutions is a manufacturer of electromagnetic interference filtering products for military and aerospace applications. Consideration for the acquisition consisted of 964,912 shares of the Company’s common stock with an estimated fair value of $8,856 and $2,200 in cash. Of the cash portion of the consideration, the Company paid $155 at the time of the consummation of the acquisition and through December 31, 2024 the Company paid an additional $1,523. The remaining $522 cash portion of the consideration is payable in quarterly installments of $174 through June 2025.

 

The merger agreement with EMI Solutions provided that in the event that Legacy Mobix did not complete an initial public offering (including the Merger) within twenty-four months following the completion of the acquisition of EMI Solutions, the sellers could require the Company to pay all unpaid cash consideration and provided the sellers a “put right” wherein the sellers could require that the Company repurchase the 964,912 shares of common stock for a cash amount equal to $6.84 per share. The Company evaluated the terms of the related agreement and concluded that the shares of common stock issued as consideration were contingently redeemable common stock, and required recognition as temporary equity, because the events that determine whether the Company will be required to repurchase the 964,912 shares of its common stock for cash are not within the Company’s control. At the time of completion of the acquisition, the Company estimated the fair value of the contingently redeemable common stock at $8,856, based upon the fair value of the Legacy Mobix common stock, adjusted to include the fair value of the put right. The Company estimated the fair value of the put right using the Black-Scholes option pricing model with the following assumptions: expected volatility of 55.0%; no expected dividend yield; risk-free interest rate of 4.5%; and a contractual term of two years. The Company included this amount as part of the value of the purchase consideration. After the Closing of the Merger with Chavant on December 21, 2023, the common stock was no longer contingently redeemable, and the Company reclassified the value of the contingently redeemable common stock to permanent equity at its carrying value of $8,856, with no gain or loss recognized.

 

15

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

The Company estimated the useful life of customer relationships is fifteen years, the useful life of the trade name is two years and the useful life of the backlog is one year. The goodwill is primarily attributed to expected synergies for the combined operations and is not deductible for income tax purposes.

 

RaGE Systems, Inc.

 

On May 21, 2024, the Company completed the acquisition of RaGE Systems when the Company acquired all of the issued and outstanding common shares of RaGE Systems pursuant to a business combination agreement (the “RaGE Business Combination Agreement”). RaGE Systems specializes in developing products for 5G communications, mmWave imaging, and software defined radio targeting the commercial, industrial, and defense and aerospace sectors. Aggregate consideration for the acquisition was $9,518, consisting of 3,214,045 shares of the Company’s Class A Common Stock having a fair value of $7,682 and $2,000 in cash, of which the Company paid $200 during the year ended September 30, 2024. Of the remainder, $1,000 is currently payable and the remaining $800 will be payable on April 15, 2025. The Company also entered into employment agreements with each of the RaGE stockholders.

 

The Company estimated the useful lives of the customer relationships, developed technology and trade name intangible assets are twelve years, seven years, and two and one-half years, respectively. The goodwill is primarily attributed to expected synergies for the combined operations and is not deductible for income tax purposes.

 

Pursuant to the RaGE Business Combination Agreement, the RaGE stockholders are entitled to receive possible earn-out payments of up to $8,000, payable in a combination of cash and shares of the Company’s Class A Common Stock, based upon both (i) the attainment of certain financial targets measured over calendar years 2024 and 2025 and (ii) continued employment with the Company (the “RaGE Earn-out”). Because the RaGE Earn-out arrangement is linked to continued employment with the Company in the post-acquisition period, the Company determined that the related cost must be recognized as an operating expense in the post-acquisition period, and no portion was accounted for as part of the purchase consideration. As of December 31, 2024, the Company estimated the amount of the payments it expects to make under the RaGE Earn-out, based upon its expectation of the level of achievement of the financial targets over the measurement period, and for the three months ended December 31, 2024 and 2023, the Company recognized expense of $1,646 and $0, respectively, which is included in selling, general and administrative expenses in the condensed consolidated statements of operations and comprehensive income (loss).

 

Pro forma information

 

The following table shows unaudited pro forma net revenue and net loss of the Company for the three months ended December 31, 2023, as if the acquisitions of EMI Solutions and RaGE Systems had each been completed as of October 1, 2022. The unaudited pro forma information is presented for informational purposes only and is not necessarily indicative of future operations or results had the acquisitions occurred on October 1, 2022.

 Schedule of Unaudited ProForma Net Revenues and Net income (Loss)

       
   

Three months ended

December 31, 2023

 
       
Net revenue   $ 2,276  
Net loss   $ (259 )

 

16

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Note 5 — Inventory

 

Inventory consists of the following:

 Schedule of Inventory

    December 31,     September 30,  
    2024     2024  
             
Raw materials   $ 1,131     $ 1,550  
Finished goods     111       175  
Total inventory   $ 1,242     $ 1,725  

 

Note 6 — Property and Equipment, net

 

Property and equipment, net consists of the following:

Schedule of Property and Equipment Net 

    Estimated Useful   December 31,     September 30,  
    Life (years)   2024     2024  
                 
Equipment and furniture   5 - 7   $ 964     $ 948  
Laboratory equipment   5     687       687  
Leasehold improvements   Shorter of estimated useful life or remaining lease term     891       891  
Property and equipment, gross         2,542       2,526  
Less: Accumulated depreciation         (1,472 )     (1,349 )
Property and equipment, net       $ 1,070     $ 1,177  

 

Depreciation expense for the three months ended December 31, 2024 and 2023 was $123 and $113, respectively.

 

Note 7 — Intangible Assets, net

 

Intangible assets, net consist of the following:

Schedule of Intangible Assets Net

 

    Estimated   December 31, 2024     September 30, 2024  
    Useful Life
(years)
  Gross     Accumulated
Amortization
    Net     Gross     Accumulated
Amortization
    Net  
                                         
Developed technology   7 – 10   $ 5,689     $ (2,361 )   $ 3,328     $ 5,689     $ (2,216 )   $ 3,473  
Customer relationships   12 – 15     11,900       (687 )     11,213       11,900       (458 )     11,442  
Trade names   2 – 2.5     300       (101 )     199       300       (68 )     232  
Backlog   1     300       (300 )           300       (236 )     64  
        $ 18,189     $ (3,449 )   $ 14,740     $ 18,189     $ (2,978 )   $ 15,211  

 

The Company recorded amortization expense related to intangible assets of $471 and $237 during the three months ended December 31, 2024 and 2023, respectively. The weighted-average remaining lives of intangible assets as of December 31, 2024 were developed technology 5.7 years; customer relationships 12.3 years; and trade names 1.7 years.

 

17

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Estimated future amortization expense for intangible assets by fiscal year as of December 31, 2024 is as follows:

Schedule of Estimated Future Amortization Expense for Intangible Assets

 

Years ending September 30,      
2025 (remaining nine months)   $ 1,222  
2026     1,589  
2027     1,510  
2028     1,498  
2029     1,498  
Thereafter     7,423  
Total   $ 14,740  

 

Note 8 — Goodwill

 

The following table summarizes changes in the carrying amount of goodwill during the three months ended December 31, 2024 and 2023.

Schedule of Changes in Carrying Amount of Goodwill

 

             
   

Three months ended

December 31,

 
    2024     2023  
             
Balance at beginning of period   $ 16,066     $ 5,217  
Acquisition of EMI Solutions           5,542  
Balance at end of period   $ 16,066     $ 10,759  

 

Note 9 — Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consist of the following:

Schedule of Accrued Expenses and Other Current Liabilities

 

    December 31,     September 30,  
    2024     2024  
             
Accrued compensation and benefits   $ 1,887     $ 1,770  
Accrued professional fees     593       340  
Accrued interest     162       177  
Deferred revenue     1,153       1,076  
Committed equity facility fees     1,553       1,553  
Unpaid Merger-related transaction costs     1,090       1,090  
RaGE Earn-out     3,504       2,098  
Other     1,952       2,221  
Total accrued expenses and other current liabilities   $ 11,894     $ 10,325  

 

Note 10 — Debt

 

Debt consists of the following:

Schedule of Debt

 

    December 31,     September 30,  
    2024     2024  
             
Notes payable   $ 794     $ 598  
7% promissory notes – related parties     2,495       2,495  
Notes payable – related parties     330       330  
Total debt     3,619       3,423  
Less: Amounts classified as current     (2,746 )     (2,141 )
Noncurrent portion   $ 873     $ 1,282  

 

18

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Notes Payable

 

In December 2024, the Company entered into a $200 note payable with a bank for net proceeds of $195. The note has an eighteen month term and requires weekly payments totaling $282, including finance charges. The note is secured by substantially all of the Company’s assets and is guaranteed by an officer and director of the Company.

 

Also in December 2024, the Company entered into an agreement for the purchase and sale of future receipts with an unrelated buyer pursuant to which the Company agreed to sell to the buyer certain future trade receipts in the aggregate amount of $710 (the “Future Receipts Purchased Amount”) for net proceeds to the Company of $480. Under the agreement, the Company granted the buyer a security interest in all of the Company’s present and future accounts receivable in an amount not to exceed the Future Receipts Purchased Amount. The Company must repay the Future Receipts Purchased Amount in weekly installments ranging from $9 to $22 through September 2025.

 

During the quarter ended December 31, 2024, the Company and the holders of two notes agreed to convert the outstanding principal and accrued interest, totaling $545, into 631,805 shares of the Company’s Class A Common Stock. The Company recognized a loss on the extinguishment of debt of $283, which is included in “Other non-operating losses, net” in the condensed consolidated statements of operations and comprehensive income (loss).

 

During the three months ended December 31, 2023, the Company entered into two promissory notes having an aggregate principal amount of $250 with unrelated investors to meet its working capital needs. The Company entered into a $150 note payable with a bank for net proceeds of $146. The note had a thirteen month term, required weekly payments totaling $216 and was guaranteed by an officer and director of the Company. The other note had a principal amount of $100, was unsecured, bears interest at 6%, and was repaid by the Company in February 2024.

 

As of December 31, 2024, notes payable having an aggregate remaining principal balance of $794 were outstanding and are included in “Notes payable” and “Notes payable, noncurrent” in the condensed consolidated balance sheet.

 

7% Promissory Notes — Related Parties

 

The Company has two outstanding promissory notes with related parties which the Company assumed in 2020 as part of an asset acquisition. The promissory notes bear interest at 7% per annum, are unsecured and do not require principal payments prior to the maturity date. The notes had an initial maturity date of August 2022, but were amended in May 2022 to extend their maturity to July 2023. During the three months ended December 31, 2024 and 2023, the Company made no principal payments on these notes and as of December 31, 2024 an aggregate principal amount of $2,495 remains outstanding.

 

In October 2024, the Company and the holder of one promissory note, having a principal balance of $1,326, agreed to extend the payment terms. Under the agreement, the Company is obligated repay the note in monthly payments of varying amounts through September 2026. As a result of this agreement, the Company reclassified $802 of the principal balance to “Notes payable — related parties, noncurrent” in the condensed consolidated balance sheet as of December 31, 2024. The portion of the 7% promissory notes due within one year is included in “Notes payable — related parties, current” in the consolidated balance sheet.

 

Notes Payable — Related Parties

 

As of December 31, 2024 and September 30, 2024, the Company had one outstanding note payable to a related party, with a principal balance of $330. The note matured in November 2024 and is currently payable. The note is unsecured and bears interest at 16% per annum. During the three months ended December 31, 2024 and 2023, the Company made principal payments of $0 and $344 on notes payable—related parties.

 

SAFEs

 

In connection with the Merger, all of the outstanding SAFEs, representing an original purchase amount of $1,000, were converted into 150,953 shares of the Company’s Class A Common Stock and the $1,512 carrying amount of these SAFEs was credited to equity, with no gain or loss recognized. There were no SAFEs outstanding during the three months ended December 31, 2024. The Company remeasured the SAFEs to fair value at each reporting date. For the three months ended December 31, 2023, the Company recorded an increase in the fair value of the SAFEs of $10, which is included in “Other non-operating losses, net” in the condensed consolidated statements of operations and comprehensive income (loss).

 

19

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Convertible Notes

 

During the three months ended December 31, 2023, the Company issued convertible notes having an aggregate principal amount of $200 to unaffiliated investors. In connection with the Merger, all outstanding convertible notes were converted into 30,045 shares of the Company’s Class A Common Stock and the $206 carrying amount of the notes and accrued interest thereon was credited to equity, with no gain or loss recognized.

 

Note 11 — Fair Value Measurements

 

The carrying amounts of the Company’s cash, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company believes the aggregate carrying value of debt approximates its fair value as of December 31, 2024 and September 30, 2024 because the notes payable, the 7% promissory notes - related parties, the notes payable - related parties each mature within one to two years of the respective balance sheet dates.

 

Fair Value Hierarchy

 

Liabilities measured at fair value on a recurring basis as of December 31, 2024 are as follows:

 Schedule of Fair Value Assets And Liabilities Measured On Recurring Basis

 

    Level 1     Level 2     Level 3     Total  
Earnout liability   $     $     $ 3,620     $ 3,620  
PIPE Common Warrants                 4,429       4,429  
Private Warrants                 368       368  
                                 
Total   $     $     $ 8,417     $ 8,417  

 

The Company classifies the earnout liability, the PIPE Common Warrants and the Private Warrants as Level 3 financial instruments due to the judgment required to develop the assumptions used and the significance of those assumptions to the fair value measurement. No financial instruments were transferred between levels of the fair value hierarchy during the three months ended December 31, 2024 or 2023. The following table provides a reconciliation of the balance of financial instruments measured at fair value on a recurring basis using Level 3 inputs:

Schedule of Fair Value Measured On Recurring Basis Unobservable Input Reconciliation 

 

Three months ended December 31, 2024:  

Earnout

Liability

   

Liability Classified

Warrants

 
Balance, September 30, 2024   $ 1,680     $ 2,139  
Change in fair value included in net loss     1,940       2,658  
                 
Balance, December 31, 2024   $ 3,620     $ 4,797  

 

Three months ended December 31, 2023:  

Earnout

Liability

   

Liability Classified

Warrants

    PIPE Make-Whole Liability     SAFEs  
Balance, September 30, 2023   $     $     $     $ 1,512  
Liabilities recognized     33,559       783       2,071        
Conversion to Class A Common Stock in the Merger                       (1,522 )
Change in fair value included in net income     (24,764 )     60       2,904       10  
                                 
Balance, December 31, 2023   $ 8,795     $ 843     $ 4,975     $  

 

20

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Earnout Liability

 

The Company estimates the fair value of the earnout liability using a Monte Carlo simulation model that utilizes significant assumptions, including volatility, expected term and risk-free rate that determine the probability of achieving the earnout conditions. The following table summarizes the assumptions used in estimating the fair value of the earnout liability at the respective dates:

 Schedule of Fair Value of Earnout Liability

 

    December 31,
2024
    September 30,
2024
 
Stock price   $ 1.70     $ 1.06  
Expected volatility     75.0 %     70.0 %
Risk-free rate     4.4 %     3.6 %
Contractual term     7.0 years       7.2 years  

 

PIPE Common Warrants

 

The Company estimates the fair value of the PIPE Common Warrants using the Black-Scholes option pricing model, which utilizes significant assumptions, including volatility, expected term and risk-free rate. The following table summarizes the assumptions used in estimating the fair value of the PIPE Common Warrants at the respective dates:

 

    December 31,
2024  
    September 30,
2024
 
Stock price   $ 1.70     $ 1.06  
Expected volatility     56.3 %     55.7 %
Risk-free rate     4.2 – 4.4 %     3.5 – 3.9 %
Contractual term     1.0 – 5.0 years       1.1 – 5.1 years  

 

Note 12 — Leases

 

The Company has entered into operating leases for office space. The leases have remaining terms ranging from 1.0 to 2.7 years and expire at various dates through August 2027. The leases do not contain residual value guarantees or restrictive covenants. The lease covering the Company’s 19,436 square foot headquarters in Irvine, California provides the Company an option to extend the lease for one additional five-year term, with rent at the then prevailing market rate. The lease requires a security deposit of $400, which is recorded in other assets in the condensed consolidated balance sheets.

 

Effective October 1, 2024, the Company entered into an operating lease with a related party for a 6,149 square foot facility in Irvine, California used for the design, manufacture and sale of the Company’s interconnect products. The lease has a term of fifteen months, with monthly rent payments of $12, and requires a security deposit of $30. Rent paid under the lease was $35 for the three months ended December 31, 2024. In connection with the lease, the Company recognized a right-of-use asset of $162. As of December 31, 2024, an operating lease liability under this lease of $132 is included in “Operating lease liabilities, current” in the condensed consolidated balance sheets.

 

The following lease costs are included in the condensed consolidated statements of operations and comprehensive income (loss):

 Schedule of Lease Costs

    2024     2023  
   

Three months ended

December 31,

 
    2024     2023  
Operating lease cost   $ 158     $ 100  
Short-term lease cost     11       2  
Total lease cost   $ 169     $ 102  

 

Cash paid for amounts included in the measurement of operating lease liabilities for the three months ended December 31, 2024 and 2023 was $189 and $136, respectively. As of December 31, 2024, the weighted-average remaining lease term was 2.4 years, and the weighted-average discount rate was 15.6%.

 

The Company has amended an office lease to provide for the use of additional space, which is not yet available for the Company’s use. At such time as the additional space is available to it—which the Company anticipates will occur in 2025—the Company expects to recognize an increase in the right-of-use asset and lease liability of approximately $814. There were no other leases that had not yet commenced as of December 31, 2024 that will create significant additional rights and obligations for the Company.

 

21

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

The following table reconciles the undiscounted cash flows to the operating lease liabilities recorded on the condensed consolidated balance sheet as of December 31, 2024:

 Schedule of Operating Lease Liability Maturity

Years ending September 30,      
2025 (remaining nine months)   $ 569  
2026     675  
2027     532  
Total minimum lease payments     1,776  
Less: imputed interest     (292 )
Present value of future minimum lease payments     1,484  
Less: current obligations under leases     (583 )
Long-term lease obligations   $ 901  

 

Note 13 — Commitments and Contingencies

 

Litigation

 

From time to time, the Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. The Company does not believe it is currently a party to any material legal proceedings, nor is the Company aware of any other pending or threatened litigation that the Company believes would have a material adverse effect on the Company’s business, operating results, cash flows or financial condition should such litigation be resolved unfavorably.

 

Indemnifications

 

In the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with customers, suppliers and vendors. Pursuant to these provisions, the Company may be obligated to indemnify such parties for losses or claims suffered or incurred in connection with its service, breach of representations or covenants, intellectual property infringement or other claims made against such parties. These provisions may limit the time within which an indemnification claim can be made. The Company has not in the past incurred significant expense defending against third party claims, nor has it incurred significant expense under its standard service warranties or arrangements with its customers, suppliers and vendors. Accordingly, the Company has not recognized any liabilities for these indemnification provisions as of December 31, 2024 or September 30, 2024.

 

Note 14 — Income Taxes

 

The Company recorded a provision (benefit) for income taxes of $(2) and $(1,280) for the three months ended December 31, 2024 and 2023, respectively. The Company calculated the provision (benefit) for income taxes for the three months ended December 31, 2024 and 2023 using the discrete year-to-date method. For the three months ended December 31, 2024, the Company’s provision (benefit) for income taxes differs from an amount calculated based on statutory tax rates principally due to the Company recording a valuation allowance against the net operating losses it generated during the period. The Company establishes a valuation allowance when necessary to reduce the carrying amount of its deferred tax assets when it is more likely than not that the deferred tax assets will not be realized. In evaluating the Company’s ability to realize deferred tax assets, the Company considers all available positive and negative evidence, including historical operating results, potential limitations on the Company’s ability to carry forward net operating losses, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Based on these factors, the Company has established a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.

 

In connection with the December 2023 acquisition of EMI Solutions, during the three months ended December 31, 2023 the Company recognized additional deferred tax liabilities totaling $1,084 associated with acquired intangible assets. Based on the availability of these tax attributes, the Company determined that it expects to realize a greater portion of its existing deferred tax assets and for the three months ended December 31, 2023 the Company recognized an income tax benefit of $1,280 for the resulting reduction of the valuation allowance on its deferred tax assets.

 

22

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Note 15 — Equity

 

In connection with the Merger, the Company adopted its amended and restated certificate of incorporation and amended and restated bylaws. The amended and restated certificate of incorporation authorizes the issuance of preferred stock, Class A Common Stock and Class B Common Stock. As of December 31, 2024, the board of directors had not designated any series of preferred stock, and no shares of preferred stock were issued or outstanding.

 

During the three months ended December 31, 2024, the Company sold 521,739 shares of its Class A Common Stock to an unaffiliated investor for net proceeds of $600. Also during the three months ended December 31, 2024, holders of 125,000 shares of the Company’s Class B Common Stock elected to convert such shares into the same number of shares of the Company’s Class A Common Stock.

 

During the three months ended December 31, 2023, Legacy Mobix sold 482,171 shares of its common stock at various dates in private placements for net proceeds of $3,286. In connection with the issuance of these shares, Legacy Mobix also granted one investor a warrant to purchase 27,413 shares of common stock at a price of $0.01 per share. The warrant is immediately exercisable and has a term of one year. The Company determined the warrant to be a freestanding equity instrument with no subsequent remeasurement. The Company determined the amount recognized within additional paid-in capital by allocating the proceeds received among the shares of common stock and the warrant issued based on their relative fair values.

 

As of December 31, 2024, the number of shares of Class A Common Stock available for issuance under the Company’s amended and restated articles of incorporation were as follows:

 Schedule of Common Stock Available for Issuance

         
Authorized number of shares of Class A Common Stock     285,000,000  
Class A Common Stock outstanding     34,652,774  
Reserve for conversion of Class B Common Stock     2,004,901  
Reserve for exercise of the Public Warrants and Private Warrants     9,000,000  
Reserve for exercise of other common stock warrants     9,428,779  
Reserve for Earnout shares     3,500,000  
Reserve for RaGE Earn-out     1,285,618  
Stock options and RSUs outstanding     8,337,727  
Awards available for grant under 2023 Equity Incentive Plan     132,247  
Awards available for grant under 2023 Employee Stock Purchase Plan     687,055  
Common stock available for issuance     215,970,899  

 

The Company has never declared or paid any dividends on any class of its equity securities and does not expect to do so in the near future.

 

Note 16 — Warrants

 

Outstanding warrants consist of the following:

 Schedule of Outstanding Warrants

    December 31, 2024     September 30, 2024  
Public Warrants     6,000,000       6,000,000  
Private Warrants     3,000,000       3,000,000  
PIPE Warrants     1,750,000       1,750,000  
PIPE Common Warrants     5,755,396       5,755,396  
Other warrants     1,923,383       2,170,403  
Total     18,428,779       18,675,799  

 

23

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Liability-Classified Warrants

 

The Company accounts for the Private Warrants as liabilities because they do not meet the derivative scope exception for contracts in the Company’s own stock. At the time of Closing, the Company estimated the aggregate fair value of the Private Warrants using the Black-Scholes option-pricing model and recognized a liability of $150. As of December 31, 2024, all of the Private Warrants remained outstanding and the Company adjusted the carrying amount of the liability to its estimated fair value of $368. As a result of changes in the fair value of the liability, the Company recorded non-cash losses of $38 and $60 for the three months ended December 31, 2024 and 2023, which are included in “Change in fair value of warrants” in the condensed consolidated statements of operations and comprehensive income (loss).

 

The Company also accounts for the PIPE Common Warrants—issued in a July 2024 private placement—as liabilities because they do not meet the derivative scope exception for contracts in the Company’s own stock. As of December 31, 2024, the Company adjusted the carrying amount of the liability for the PIPE Common Warrants to its estimated fair value of $4,429, included in “Other noncurrent liabilities” in the condensed consolidated balance sheets. As a result of changes in the fair value of the liability, the Company recorded a non-cash loss of $2,620 for the three months ended December 31, 2024, which is included in “Change in fair value of warrants” in the condensed consolidated statements of operations and comprehensive income (loss).

 

Other Warrants

 

In connection with the Merger, all of Legacy Mobix’s outstanding warrants were assumed by the Company and converted into the same number of warrants to purchase shares of the Company’s Class A Common Stock, with no change to their exercise prices or other terms. Subsequent to the Merger, warrants to purchase an aggregate of 373,031 shares were exercised and converted into 369,671 shares of Class A Common Stock, with no cash proceeds to the Company.

 

During the three months ended December 31, 2023, the Company issued warrants to purchase an aggregate of 51,020 shares of its common stock at $0.01 per share in connection with borrowings and warrants to purchase an aggregate of 27,413 shares of common stock at a price of $0.01 per share to investors in connection with the sale of shares of its common stock. The Company also agreed to issue warrants to purchase 130,000 shares of its Class A Common Stock at $0.01 per share to a service provider, in respect of services rendered to Legacy Mobix prior to the Merger.

 

In addition, during the three months ended December 31, 2023 Legacy Mobix failed to repay the principal amount of a note payable by its maturity date and was obligated to issue warrants to purchase 78,000 shares of its Class A Common Stock at $0.01 per share to the lender as additional consideration. During the three months ended December 31, 2023, the Company recognized $633 of interest expense for the estimated fair value of these warrants.

 

Note 17 — Stock-Based Compensation

 

The Company’s 2023 Equity Incentive Plan provides for the issuance of stock options, restricted stock awards, RSUs and other stock-based compensation awards to employees, directors, officers, consultants or others who provide services to the Company. The Company has reserved 2,290,183 shares of its Class A Common Stock for issuance under the terms of the 2023 Equity Incentive Plan. Prior to the Merger, Legacy Mobix had three equity incentive plans which provided for the issuance of stock-based compensation awards.

 

Restricted Stock Units

 

In connection with the Merger, all of Legacy Mobix’s RSUs were assumed by the Company and converted into an RSU covering the same number of shares of the Company’s Class A Common Stock.

 

Prior to the Merger, Legacy Mobix agreed, contingent upon closing of the Merger, to issue an aggregate of 5,000,000 RSUs (of which 999,999 were subsequently modified to common stock warrants upon the holder’s termination of employment) to certain of its officers and key employees over three years, beginning on the first anniversary of the Closing of the Merger. Because the vesting of these awards was subject to both a service condition and a performance condition (the completion of the Merger), the Company determined that vesting of the awards was not probable and did not recognize any stock-based compensation expense for these awards prior to the Closing. Upon Closing, the performance condition was satisfied, and vesting of the awards is subject only to a service condition. As a result, the Company recognizes the value of these awards over the requisite service period and during the three months ended December 31, 2023, the Company recognized stock-based compensation expense of $10,858 relating to these RSUs and warrants, which included a catch-up for the portion of the service period completed prior to the performance condition being satisfied.

 

24

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

During the three months ended December 31, 2024, the Company and a former employee entered into certain agreements wherein the Company agreed to accelerate the vesting of 999,999 common stock warrants and grant the holder an additional 250,000 common stock warrants. The warrants are immediately exercisable and have an exercise price of $0.01 per share. Subsequently, the Company agreed to cancel 450,000 of these common stock warrants and replace them with the same number of fully vested RSUs. As a result of the acceleration of vesting and the grant of the warrants, during the three months ended December 31, 2024 the Company recognized additional stock-based compensation expense of $6,917.

 

A summary of activity in the Company’s RSUs for the three months ended December 31, 2024 is as follows:

Schedule of Activity in the Company's RSUs 

    Number of
units
    Weighted-
Average
Grant Date
Fair Value
per Unit
 
Outstanding at September 30, 2024     4,463,253     $ 7.93  
Granted     1,707,775       1.43  
Forfeited     (13,093 )     6.84  
Vested     (510,000 )     0.79  
Outstanding at December 31, 2024     5,647,935       6.61  

 

Unrecognized compensation expense related to RSUs was $20,586 as of December 31, 2024 and is expected to be recognized over a weighted-average period of 2.7 years.

 

Stock Options

 

Stock option activity for the three months ended December 31, 2024 is as follows:

 

Schedule of Stock Option Activity

    Number of
Options
    Weighted-
Average
Exercise Price
per Share
    Weighted-
Average
Remaining
Contractual
Term
(years)
 
Outstanding at September 30, 2024     2,740,846     $ 4.89          
Forfeited     (51,054 )     6.77          
Outstanding at December 31, 2024     2,689,792       4.85       6.4  
Exercisable at December 31, 2024     2,432,544       4.68       6.4  

 

Unrecognized stock-based compensation expense related to stock options, totaling $868 as of December 31, 2024, is expected to be recognized over a weighted-average period of 1.6 years. The aggregate intrinsic value of stock options outstanding and stock options exercisable as of December 31, 2024 was $990 and $990, respectively. The total intrinsic value of options exercised during the three months ended December 31, 2024 and 2023 was $0 and $1,639, respectively. The total fair value of options that vested during the three months ended December 31, 2024 and 2023 was $179 and $903, respectively.

 

25

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

The weighted-average grant date fair value of options granted during the three months ended December 31, 2023 was $3.50; no options were granted during the three months ended December 31, 2024. The fair value of stock options granted was estimated with the following assumptions:

 Schedule of Weighted-Average Grant Date Fair Value of Options Granted

    Three months ended December 31, 2023  
    Range  
    Low     High  
Expected volatility     54.8 %     55.6 %
Expected dividend yield     0 %     0 %
Risk-free interest rate     3.9 %     4.4 %
Expected term (years)     4.5       5.3  

 

The condensed consolidated statements of operations and comprehensive income (loss) include stock-based compensation expense as follows:

Schedule of Consolidated Statements of Operations and Comprehensive Loss 

             
    Three months ended
December 31,
 
    2024     2023  
Cost of revenue   $ 16     $  
Research and development     81       501  
Selling, general and administrative     9,705       12,204  
Total stock-based compensation expense   $ 9,802     $ 12,705  

 

Note 18 — Net Income (Loss) Per Share

 

The Company computes net income (loss) per share of Class A and Class B Common Stock using the two-class method. Basic net income (loss) per share is computed using the weighted-average number of shares outstanding during the period. Diluted net income (loss) per share is computed using the weighted-average number of shares and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities consist of stock options, warrants, RSUs and other contingently issuable shares. The dilutive effect of outstanding stock options, warrants, RSUs and other contingently issuable shares is reflected in diluted earnings per share by application of the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock method, as applicable. The computation of the diluted net income (loss) per share of Class A Common Stock assumes the conversion of Class B Common Stock, while the diluted net income (loss) per share of Class B Common Stock does not assume the conversion of those shares.

 

In periods where the Company has a net loss, most potentially dilutive securities are not included in the computation as their impact is anti-dilutive; those potentially dilutive securities whose impact is dilutive are included in the computation. In periods where their effect is dilutive, potentially dilutive securities are included in the computation of diluted income (loss) per share as if the underlying shares had been issued as of the later of the beginning of the fiscal period or the date of issuance of those securities. Inclusion of those securities under the if-converted method increases both the net loss for the period and the number of shares used in the per share computation and is dilutive to the Company’s net income (loss) per share.

 

26

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Schedule of Earnings Per Share Basic and Diluted

                         
   

Three months ended

December 31,

 
    2024     2023  
    Class A     Class B     Class A     Class B  
Basic net income (loss) per share:                                
Numerator:                                
Allocation of net income (loss)   $ (18,754 )   $ (1,085 )   $ 834     $ 101  
Denominator:                                
Weighted-average shares outstanding     36,324,198       2,101,368       18,617,656       2,254,901  
Basic net income (loss) per share   $ (0.52 )   $ (0.52 )   $ 0.04     $ 0.04  
                                 
Diluted net income (loss) per share:                                
Numerator:                                
Allocation of net income (loss)   $ (18,754 )   $ (1,085 )   $ 834     $ 101  
Reallocation of net loss as a result of conversion of Class B to Class A Common Stock     (1,085 )           101        
Reallocation of net income (loss)                       (11 )
Allocation of net income (loss)   $ (19,839 )     (1,085 )     935       90  
                                 
Denominator:                                
Number of shares used in basic earnings per share calculation     36,324,198       2,101,368       18,617,656       2,254,901  
Conversion of Class B to Class A Common Stock     2,101,368             2,254,901        
Dilutive effect of stock options, warrants and RSUs                 2,443,514        
Number of shares used in per share computation     38,425,566       2,101,368       23,316,071       2,254,901  
Diluted net income (loss) per share   $ (0.52 )   $ (0.52 )   $ 0.04     $ 0.04  

 

For purposes of applying the if converted method or treasury stock method for calculating diluted earnings per share, the Public Warrants, Private Warrants, PIPE Common Warrants, and Placement Agent Warrants result in anti-dilution. For the three months ended December 31, 2024, the RSUs and stock options also result in anti-dilution. Therefore, these securities are not included in the computation of diluted net loss per share. The Earnout Shares and shares issuable under the RaGE Earn-out were not included for purposes of calculating the number of diluted shares outstanding because the number of dilutive shares is based on a contingency which had not been met, and the contingency was not resolved, during the periods presented herein.

 

The potential shares of Class A Common Stock that were excluded from the computation of diluted net income (loss) per share attributable to stockholders for the periods presented because including them would have an antidilutive effect were as follows:

Schedule of Antidilutive Shares 

             
    Three months ended
December 31,
 
    2024     2023  
Public Warrants and Private Warrants     9,000,000       9,000,000  
PIPE Common Warrants     5,755,396        
Other common stock warrants     763,384        
Earnout shares     3,500,000       3,500,000  
Shares issuable under RaGE Earn-out     1,285,618        
RSUs     5,647,935        
Stock options     2,689,792       1,690,476  
PIPE make-whole shares           1,052,030  
Antidilutive Shares     28,642,125       15,242,506  

 

27

 

MOBIX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(unaudited, in thousands, except share and per share amounts)

 

Note 19 — Concentrations

 

For the three months ended December 31, 2024, one customer accounted for 67% of the Company’s net revenue. For the three months ended December 31, 2023, two customers accounted for 67% of the Company’s net revenue. No other customer accounted for more than 10% of net revenue in the respective periods.

 

As of December 31, 2024, one customer had a balance due that represented 71% of the Company’s total accounts receivable. As of September 30, 2024, two customers had balances due that represented 71% of the Company’s total accounts receivable.

 

Note 20 — Geographical Information

 

Revenues by Geographic Region

 

The Company’s net revenue by geographic region, based on ship-to location, are summarized as follows:

Schedule of Company’s Net Revenue by Geographic Region 

             
   

Three months ended

December 31,

 
    2024     2023  
United States   $ 3,018     $ 268  
Other     151       17  
Total net revenue   $ 3,169     $ 285  

 

Long-Lived Assets

 

Substantially all of the Company’s long-lived assets are located in the United States.

 

Note 21 — Subsequent Events

 

In January 2025, the Company entered into a stock purchase agreement with an unaffiliated investor pursuant to which the investor may purchase 169,492 shares of its Class A Common Stock, together with warrants to purchase 169,492 shares of its Class A Common Stock, for net proceeds of $200. The warrants have an exercise price of $1.18 per share, are immediately exercisable and have a five-year term. Under the stock purchase agreement, the investor may purchase up to an additional 677,966 shares of the Company’s Class A Common Stock at a price of $1.18 per share at any time prior to February 14, 2025.

 

28

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements included the Part I, Item 1 of this Quarterly Report on Form 10-Q. The following discussion contains forward-looking statements based upon current beliefs that involve risks, uncertainties, and assumptions, such as statements regarding our plans, objectives, expectations, intentions, and projections. Our actual results and the timing of selected events could differ materially from those described in or implied by these forward-looking statements as a result of several factors, including those set forth under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. You should carefully read the “Risk Factors” section, the Cautionary Note Regarding Forward-Looking Statements as well as the risks and uncertainties set forth in our other SEC filings to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements.

 

All amounts in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are in thousands, except numbers of shares and per share amounts.

 

Overview

 

Based in Irvine, California, Mobix Labs designs, develops and sells components and systems for advanced wireless and wired connectivity, radio frequency (“RF”), switching and electromagnetic interference (“EMI”) filtering technologies. Our solutions are used in the consumer commercial, industrial, automotive, medical, aerospace, defense and other markets. To enhance our product portfolio, we also intend to pursue acquisitions of companies with existing revenue which can be scaled, and which possess technologies that accelerate the speed, accessibility, and efficiency of disruptive or more efficient communications solutions, and which will also allow us to expand into strategically aligned industries. Our wireless systems solutions include products for advanced RF and millimeter wave (“mmWave”) 5G communications, mmWave imaging, software defined radio and custom RF integrated circuits (“ICs”) targeting the commercial, industrial, and defense and aerospace sectors. Our interconnect products, including EMI filter inserts and filtered and non-filtered connectors, are designed for and are currently used in aerospace, military, defense and medical applications. Our True Xero active optical cables (“AOCs”) are designed to meet customer needs for high-quality active optical cable solutions at an affordable price. These innovative technologies are designed for large and rapidly growing markets where there is increasing demand for higher performance communication and filtering systems which utilize an expanding mix of both wireless and connectivity technologies.

 

On December 21, 2023, we consummated the merger pursuant to the business combination agreement, dated November 15, 2022 (as amended, supplemented or otherwise modified, the “Business Combination Agreement”), by and among Chavant, CLAY Merger Sub II, Inc., a Delaware corporation and newly formed, wholly-owned direct subsidiary of Chavant (“Merger Sub”), and Mobix Labs, Inc. (“Legacy Mobix”), a Delaware corporation, pursuant to which, among other things, Merger Sub merged with and into Legacy Mobix, with Legacy Mobix surviving the merger as a wholly-owned direct subsidiary of Chavant (together with the other transactions related thereto, the “Merger”). In connection with the consummation of the Merger (the “Closing”), Chavant changed its name from “Chavant Capital Acquisition Corp.” to “Mobix Labs, Inc.” (the “Company”) and Legacy Mobix changed its name from “Mobix Labs, Inc.” to “Mobix Labs Operations, Inc.”

 

Throughout this discussion, unless otherwise noted or otherwise suggested by context, all references to “we,” “us” or “our” refer to Legacy Mobix prior to the consummation of the Merger, and to the Company and its subsidiaries after the consummation of the Merger.

 

We were founded with the goal of simplifying the development and maximizing the performance of wireless mmWave 5G products by designing and developing high performance, cost-effective and ultra-compact semiconductor components and solutions used for signal processing applications in wireless products. Since our inception, our corporate strategy has evolved to encompass the pursuit of acquisitions in diverse industry sectors, including aerospace, military, defense, medical and high reliability (“HiRel”) technology, as part of our commitment to enhancing communication services. We have developed and/or acquired an extensive intellectual property (“IP”) portfolio comprised of patents and trade secrets that are critical to commercializing our communication products and communications technologies. In leveraging our proprietary technology, we aim to scale the growth of revenue for our products by serving large and rapidly growing markets where we believe there are increasing demands for higher performance communication technologies, including both wireless and wired connectivity systems. We are actively pursuing customer engagements with manufacturers of wireless communications, aerospace, military, defense, medical and HiRel products.

 

29

 

In 2021, we completed the acquisition of substantially all of the assets including IP of Cosemi Technologies, Inc. (“Cosemi”), an Irvine, California-based global supplier of high-speed connectivity solutions. The acquired products and IP included a broad range of AOCs and optical engines that deliver optimal connectivity to a wide range of applications—including home entertainment, gaming, augmented reality and virtual reality, video conferencing, medical, mobile devices and monitors—and built the foundation for our current connectivity business. We believe the patented cable technology and AOC optical chip solutions from Cosemi along with our innovative wireless semiconductor technologies provide more opportunities in the wireless C-Band and mmWave 5G market as the need for faster, more reliable data transmission becomes ever more apparent, whether it is for the data center, infrastructure, home entertainment or consumer electronics market.

 

Recent Developments

 

Private Placement

 

On July 22, 2024, we entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an institutional accredited investor in connection with a private placement (the “Private Placement”). Pursuant to the Securities Purchase Agreement, on July 24, 2024, we issued an unregistered pre-funded warrant (the “Pre-Funded Warrant”) to purchase up to 2,877,698 unregistered shares of our Class A Common Stock. We also issued unregistered warrants to purchase an aggregate of 5,755,396 shares of our Class A Common Stock (“PIPE Common Warrants”). We received gross proceeds from the Private Placement of $4,000, before payment of fees and expenses to the placement agent of $415. In August 2024, the investor exercised the Pre-Funded Warrant in full, for net cash proceeds to us of $3.

 

The PIPE Common Warrants are comprised of Series A warrants to purchase up to 2,877,698 shares of Class A Common Stock (the “Series A Warrants”) and Series B warrants to purchase up to 2,877,698 shares of Class A Common Stock (the “Series B Warrants”). The PIPE Common Warrants have an exercise price of $1.39 per share and are exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Class A Common Stock upon exercise of the PIPE Common Warrants, which was obtained on January 3, 2025. The Series A Warrants will expire on January 3, 2030 and the Series B warrants will expire on January 3, 2026.

 

In connection with the Private Placement, we paid the placement agent fees and expenses of $415 and issued the placement agent warrants to purchase an aggregate of 201,439 shares of our Class A Common Stock (the “Placement Agent Warrants”). The Placement Agent Warrants have an exercise price of $1.7375 per share, became exercisable upon stockholder approval on January 3, 2025 and will expire on January 3, 2030. Moreover, upon any exercise for cash of the PIPE Common Warrants, we are obligated to pay the placement agent cash fees aggregating 8% of the gross exercise price and issue to the placement agent warrants to purchase a number of shares of our Common Stock equal to 7.0% of the aggregate number of such shares of our common stock underlying the PIPE Common Warrants.

 

We also entered into a registration rights agreement and filed with the Securities and Exchange Commission a registration statements to register for resale the shares of Common Stock issuable upon exercise of the PIPE Common Warrants, the Pre-Funded Warrants and the Placement Agent Warrants, which became effective on August 28, 2024.

 

Acquisition of RaGE Systems Inc.

 

On May 21, 2024, we completed the previously announced acquisition of RaGE Systems. RaGE Systems designs, develops and manufactures wireless systems solutions, including products for 5G communications, mmWave imaging, and software defined radio targeting the commercial, industrial, and defense and aerospace sectors. We believe the acquisition of RaGE Systems expands our expertise in wireless communications and will allow us to deliver solutions that address a wider variety of applications and markets.

 

30

 

Aggregate consideration for the acquisition of RaGE Systems consisted of 3,214,045 shares of our Class A Common Stock, having a fair value of $7,682 at the closing date, and $2,000 in cash. We also entered into employment agreements with each of the RaGE Systems stockholders. The RaGE Systems stockholders will also be entitled to receive possible earn-out payments of up to $8,000 over eight fiscal quarters, payable in a combination of cash and shares of our Class A Common Stock, based upon the satisfaction of certain financial metrics and continued employment with us. The RaGE Systems business combination agreement also provides the RaGE Systems stockholders with “piggy-back” registration rights, subject to certain requirements and customary conditions.

 

Acquisition of EMI Solutions, Inc.

 

On December 18, 2023, we completed the acquisition of EMI Solutions when we acquired all of the issued and outstanding common shares of EMI Solutions. EMI Solutions is a manufacturer of interconnect products, including electromagnetic interference filtering products for aerospace, military, defense and medical applications. We believe the acquisition of EMI Solutions complements our existing product offerings, expanded our customer base and allows us to deliver solutions that address a wider variety of applications and markets. Consideration for the acquisition of EMI Solutions consisted of 964,912 shares of Legacy Mobix common stock and $2,200 in cash. We valued the common stock at $8,856, based on the fair value of the Legacy Mobix common stock at the time of the acquisition.

 

Financing Activities

 

During the three months ended December 31, 2024, we had additional financing activity, consisting of the issuance of a note payable, an agreement for the sale and purchase of future receipts and the sale of shares of our Class A Common Stock. See “Liquidity and Capital Resources,” below, and our unaudited condensed consolidated financial statements for further details.

 

The Merger

 

We accounted for the Merger as a reverse recapitalization. Under this method of accounting, Chavant is treated as the “acquired” company for financial reporting purposes. This determination was primarily based on holders of Legacy Mobix capital stock comprising a majority of the voting power of our common stock upon consummation of the Merger and having the ability to nominate the majority of our board of directors, Legacy Mobix’ senior management comprising our senior management, and Legacy Mobix’ operations comprising our ongoing operations. Accordingly, for accounting purposes, our financial statements represent a continuation of the financial statements of Legacy Mobix with the Merger being treated as the equivalent of Legacy Mobix issuing shares for the net assets of Chavant, accompanied by a recapitalization. We recognized the net assets of Chavant as of the Closing at historical cost, with no goodwill or other intangible assets recorded. Our operations prior to the Merger are presented as those of Legacy Mobix and the accumulated deficit of Legacy Mobix has been carried forward after Closing. All issued and outstanding securities of Chavant at the time of the Closing were treated as issuances of securities by us upon the consummation of the Merger.

 

As a result of the Merger, we raised gross proceeds of $21,014, including the contribution of $1,264 of cash held in Chavant’s trust account and the $19,750 private investment in public equity (“PIPE”) at $10.00 per share of Chavant’s Class A Common Stock. Our Class A Common Stock and Public Warrants (“Public Warrants”) began trading on Nasdaq under the symbols “MOBX” and “MOBXW,” respectively, on December 22, 2023.

 

31

 

Results of Operations

 

Comparison of the Three Months Ended December 31, 2024 and 2023

 

(dollars in thousands)   Three months ended
December 31,
    Change  
    2024     2023     $     %  
                         
Net revenue   $ 3,169     $ 285       2,884       1,012 %
Cost of revenue     1,482       329       1,153       350 %
Gross profit     1,687       (44 )     1,731       nm  
                                 
Operating expenses:                                
Research and development     611       1,562       (951 )     (61 )%
Selling, general and administrative     15,706       15,663       43        
                                 
Loss from operations     (14,630 )     (17,269 )     2,639       (15 )%
                                 
Interest expense     211       857       (646 )     (75 )%
Change in fair value of earnout liability     1,940       (24,764 )     26,704       (108 )%
Change in fair value of warrants     2,658       60       2,598       nm  
Change in fair value of PIPE make-whole liability           2,904       (2,904 )     (100 )%
Merger-related transaction costs expensed           4,009       (4,009 )     (100 )%
Other non-operating losses, net     402       10       392       nm  
                                 
Loss before income taxes     (19,841 )     (345 )     (19,496 )     nm  
Provision (benefit) for income taxes     (2 )     (1,280 )     1,278       (100 )%
                                 
Net income (loss) and comprehensive income (loss)   $ (19,839 )   $ 935     $ (20,774 )     nm  

 

“nm” indicates amount is not meaningful.

 

Net Revenue

 

We derive our net revenue primarily from product sales to equipment manufacturers. We recognize product revenue when we satisfy performance obligations under the terms of our contracts and upon transfer of control when title transfers (either upon shipment to or receipt by the customer, as determined by the contractual shipping terms of the contract), net of accruals for estimated sales returns and allowances (which were not material for the three months ended December 31, 2024 and 2023). Sales and other taxes we collect, if any, are excluded from net revenue. We account for all shipping and handling as fulfillment activities and we recognize shipping revenue and any related costs concurrently with the related product revenues. Our net revenue fluctuates based on a variety of factors, including the timing of the receipt of orders from our customers, product mix, competition, global economic conditions, and other factors.

 

Our net revenue was $3,169 for the three months ended December 31, 2024 compared to $285 for the three months ended December 31, 2023, an increase of $2,884 or 1,012%. The increase principally reflects the addition of sales of our interconnect products, which we acquired in our December 2023 acquisition of EMI Solutions, and wireless systems solutions, which we acquired in our May 2024 acquisition of RaGE Systems.

 

Cost of Revenue

 

Cost of revenue includes costs of materials, contract manufacturing services for the assembly, testing and shipping products, inbound freight, amortization of acquired developed technology, inventory obsolescence charges and other product-related costs. Cost of revenue also includes employee compensation and benefits (including stock-based compensation) of employees engaged in engineering services or the manufacture or sourcing of products, facility costs and depreciation.

 

32

 

Cost of revenue was $1,482 for the three months ended December 31, 2024 compared to $329 for the three months ended December 31, 2023, an increase of $1,153 or 350%. The change principally reflects the addition of sales of our interconnect products and wireless systems solutions as discussed above.

 

Research and Development Expenses

 

Research and development expenses represent costs of our product design and development activities, including employee compensation and benefits (including stock-based compensation), outside services, design tools, supplies, facility costs, depreciation and amortization of acquired developed technology. We expense all research and development costs as incurred.

 

Research and development expenses were $611 for the three months ended December 31, 2024 compared to $1,562 for the three months ended December 31, 2023, a decrease of $951 or 61%. The decrease principally reflects lower employee compensation and benefits, lower costs for outside services and lower stock-based compensation expense resulting from the cost reduction actions we initiated during the fourth quarter of our fiscal year ended September 30, 2023. These decreases were partly offset by the addition of research and development expenses of the businesses we acquired during fiscal year 2024.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses primarily include employee compensation and benefits (including stock-based compensation) of executive and administrative staff including human resources, accounting, information technology, sales and marketing, outside professional and legal fees, insurance, advertising and promotional programs, travel and entertainment, and facility costs.

 

Selling, general and administrative expenses were $15,706 for the three months ended December 31, 2024 compared to $15,663 for the three months ended December 31, 2023, an increase of $43. The change reflects a $1,646 charge for estimated amounts payable under the RaGE Earn-out in connection with our acquisition of RaGE Systems, the addition of selling, general and administrative expenses of the businesses we acquired during fiscal 2024, higher insurance costs and higher amortization of intangible assets. These increases were largely offset by lower stock-based compensation expense. Stock based-compensation expense for the three months ended December 31, 2023 included the impact of certain awards whose vesting is contingent on both the completion of the Merger and the satisfaction of a service condition. Upon completion of the Merger, we recognized a “catch-up” of stock-based compensation expense of $10,858 for the portion of the service period that had elapsed from the date of the awards through December 31, 2023. During the three months ended December 31, 2024, we recognized additional stock-based compensation expense of $6,917 resulting from the acceleration of certain stock-based compensation awards.

 

Interest Expense

 

Interest expense consists of cash and non-cash interest related to our related and unrelated party promissory notes, notes payable and convertible notes.

 

Interest expense was $211 for the three months ended December 31, 2024 compared to $857 for the three months ended December 31, 2023, a decrease of $646 or 75%. The decrease principally reflects higher costs in the three months ended December 31, 2023 for the value of warrants to purchase shares of our common stock that we issued in connection with borrowings.

 

Change in Fair Value of Earnout Liability

 

In connection with the Merger, certain Legacy Mobix stockholders and certain holders of Legacy Mobix stock options will be entitled to receive an additional aggregate 3,500,000 shares of our Class A Common Stock based on the achievement of trading price targets following the Closing over a seven-year earnout period. We account for the Earnout Shares as liability-classified instruments because the events that determine the number of Earnout Shares to which the earnout recipients will be entitled include events that are not solely indexed to our common stock, and we remeasure the earnout liability to its estimated fair value at the end of each reporting period. Additional information relating to the earnout liability can be found in the notes to our unaudited condensed consolidated financial statements included herein.

 

33

 

We estimated the fair value of the earnout liability as of the Closing of the Merger at $33,559. As of December 31, 2024, none of the conditions for the issuance of any earnout shares had been achieved and we adjusted the carrying amount of the earnout liability to its estimated fair value of $3,620. As a result of changes in the estimated fair value of the liability, we recognized non-cash gains (losses) of $(1,940) and $24,764, respectively, for the three months ended December 31, 2024 and 2023. The changes in the estimated fair value of the earnout liability are principally due to changes in price of our Class A Common Stock during the respective periods.

 

The fair value of the earnout liability is based on a number of factors, including changes in the market price of our Class A Common Stock. We have experienced significant fluctuations in the market price of our Class A Common Stock, and may experience significant fluctuations in the future. Such price fluctuations will increase or decrease the value of the earnout liability, and we may be required to recognize additional losses or gains in our statements of operations and comprehensive income (loss), the amounts of which may be substantial.

 

Change in Fair Value of Warrants

 

We account for the PIPE Common Warrants and the Private Warrants as liabilities because they do not meet the derivative scope exception for contracts in our own stock. We estimate the aggregate fair value of the 5,755,396 PIPE Common Warrants using the Black-Scholes option-pricing model. As of December 31, 2024, we adjusted the carrying amount of the liability for the PIPE Common Warrants to its estimated fair value of $4,429. As a result of the change in the fair value of the PIPE Common Warrants, for the three months ended December 31, 2024 we recorded a non-cash loss of $2,620.

 

At the time of Closing, we estimated the aggregate fair value of the 3,000,000 Private Warrants using the Black-Scholes option-pricing model and recognized a liability of $150. As of December 31, 2024, all of the Private Warrants remained outstanding and we adjusted the carrying amount of the liability to its estimated fair value of $368. As a result of changes in the fair value of the Private Warrants, we recorded non-cash losses of $38 and $60 for the three months ended December 31, 2024 and 2023, respectively. The gains and losses are included in “Change in fair value of warrants” in the unaudited condensed consolidated statements of operations and comprehensive income (loss). Additional information relating to the PIPE Common Warrants and the Private Warrants can be found in the notes to our unaudited condensed consolidated financial statements included herein.

 

The fair value of the PIPE Common Warrants and the Private Warrants is based on a number of factors, including changes in the market price of our Class A Common Stock. We have experienced significant fluctuations in the market price of our Class A Common Stock, and may experience significant fluctuations in the future. Such price fluctuations will increase or decrease the value of the PIPE Common Warrants and the Private Warrants, and we may be required to recognize additional losses or gains in our statements of operations and comprehensive income (loss), the amounts of which may be substantial.

 

Change in Fair Value of PIPE Make-Whole Liability

 

In connection with the Merger, we agreed to issue additional shares of our Class A Common Stock to the holders of 2,454,737 shares of our Class A Common Stock in the event that the volume-weighted average price per share of our Class A Common Stock in the event that the VWAP per share of the Class A Common Stock during a specified adjustment period is less than $10.00 per share. The specified adjustment period ended on August 30, 2024 and the Company issued 1,052,029 shares of its Class A Common Stock in settlement of the liability for the Make-Whole Shares.

 

We accounted for the Make-Whole Shares as liability-classified instruments because the events that determined the number of Make-Whole Shares issuable included events that were not solely indexed to our common stock. At the time of Closing, we estimated the aggregate fair value of the liability for the Make-Whole Shares using a Monte Carlo simulation model and recorded a liability of $2,071. As a result of subsequent changes in the fair value of the liability, we recorded a non-cash loss of $2,904 for the three months ended December 31, 2023, which is included in “Change in fair value of PIPE make-whole liability” in the unaudited condensed consolidated statements of operations and comprehensive income (loss).

 

34

 

Other Non-Operating Losses, Net

 

For the three months ended December 31, 2024, other non-operating losses, net of $402 principally consist of a loss we recognized upon the conversion of the outstanding principal balance of a note payable and accrued interest thereon into shares of our Class A Common Stock.

 

Provision (Benefit) for Income Taxes

 

We account for income taxes using the asset and liability method whereby deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The effect on deferred tax assets and liabilities of a change in tax laws is recognized in the results of operations in the period the new laws are enacted. We record a valuation allowance to reduce the carrying amounts of our deferred tax assets unless it is more likely than not that such assets will be realized.

 

For the three months ended December 31, 2024, our provision (benefit) for income taxes differs from an amount calculated based on statutory tax rates principally due to our recording a valuation allowance against the net operating losses we generated during the period because we did not expect that the deferred tax asset arising from our pretax book loss of $19,841 would be realized in the future.

 

For the three months ended December 31, 2023, we recognized an income tax benefit of $1,280. In connection with our acquisitions of EMI Solutions, we recognized additional deferred tax liabilities of $1,084 associated with acquired intangible assets. Based on the availability of these tax attributes, we determined that we expect to realize a greater portion of our existing deferred tax assets and for the three months ended December 31, 2023 we recognized an income tax benefit of $1,280, principally resulting from reductions of the valuation allowance previously recorded against our deferred tax assets.

 

Liquidity and Capital Resources

 

Our primary use of cash is to fund operating expenses, working capital requirements, debt service obligations, capital expenditures and other investments.

 

We have incurred operating losses and negative cash flows as a result of our ongoing investment in product development and other operating expenses we incur. We expect to continue to incur operating losses and negative cash flows from operations associated with research and development expenses, selling, general, and administrative expenses and capital expenditures necessary to expand our operations, product offerings, and customer base with the ultimate goals of growing our business and achieving profitability in the future.

 

Cash Flows

 

The following table summarizes our unaudited condensed consolidated cash flows for the three months ended December 31, 2024 and 2023:

 

    Three months ended
December 31,
    Change  
    2024     2023     $  
Net cash used in operating activities   $ (930 )   $ (3,596 )   $ 2,666  
Net cash used in investing activities           (115 )     115  
Net cash provided by financing activities     1,069       18,418       (17,349 )
Net increase in cash     139       14,707     $ (14,568 )
Cash, beginning of period     266       89          
Cash, end of period   $ 405     $ 14,796          

 

35

 

Operating Activities

 

For the three months ended December 31, 2024, net cash used in operating activities was $930, which included the impact of our net loss of $19,839, offset by net non-cash charges of $15,520 and net decreases in working capital items of $3,389. The net non-cash charges principally consisted of stock-based compensation expense of $9,802 for stock options and restricted stock units, losses of $2,658 from the change in fair value of warrants, a $1,940 loss on the change in fair value of the earnout liability and $594 of depreciation and amortization expense. The net working capital decrease principally consisted of an increase in accrued expenses together with decreases in accounts receivable and inventory.

 

For the three months ended December 31, 2023, net cash used in operating activities was $3,596, which included the impact of our net income of $935, net non-cash credits of $5,298 and net decreases in working capital items of $767. The net non-cash credits principally consisted of the $24,764 gain on the change in fair value of the earn-out liability and a deferred income tax benefit of $1,280, partially offset by stock-based compensation expense of $12,705 for stock options and restricted stock units, $4,009 of Merger related transaction costs expensed, a $2,904 loss on the change in the fair value of the PIPE make-whole liability, $729 of expense for the issuance of warrants in connection with borrowings and $350 of depreciation and amortization expense.

 

Investing Activities

 

Net cash used in investing activities for the three months ended December 31, 2023 of $115 consisted of payments for the acquisition EMI, net of acquired cash.

 

Financing Activities

 

Net cash provided by financing activities for the three months ended December 31, 2024 of $1,069 consisted of $600 in proceeds from the issuance of common stock and $675 in proceeds under an agreement for the purchase and sale of future receipts and the issuance of a note payable. These amounts were partially offset by principal payments on notes payable of $32 and the payment of deferred consideration of $174 for the acquisition of a business.

 

Net cash provided by financing activities for the three months ended December 31, 2023 of $18,418 consisted of the $21,014 proceeds from the merger and PIPE, $3,286 in proceeds from the issuance of common stock, and $446 in proceeds from issuance of notes payable and convertible notes. These amounts were partially offset by the payment of merger-related transaction costs of $5,966 and $362 of principal payments on notes payable (including payments of $344 on notes payable—related parties).

 

Liquidity

 

As of December 31, 2024, our cash balance was $405 compared to $266 at September 30, 2024. We had a working capital deficit of $24,615 as of December 31, 2024 compared to a working capital deficit of $20,836 at September 30, 2024.

 

Our debt consists of notes payable with an aggregate amount of $794 and 7% promissory notes—related parties with an aggregate principal amount of $2,825. Of these amounts, notes having an aggregate principal amount of $1,624 have reached their maturity date and are currently due. The remainder require weekly or monthly payments in varying amounts through September 2026.

 

Our total liabilities as of December 31, 2024 were $40,310 compared to $33,558 as of September 30, 2024. The increase in our total liabilities is principally due to a $1,940 increase in the earnout liability, a $2,658 increase in the fair value of liability-classified warrants and a $1,646 increase in the liability for the RaGE Earn-out. The Business Combination Agreement provides that settlement of the earnout liability is through the issuance of shares of our Class A Common Stock; we do not expect to make any cash payments in settlement of the earnout liability.

 

Other commitments include (i) non-cancelable operating leases for equipment, office facilities and other property containing future minimum lease payments totaling $1,776 payable over the next three years, (ii) unpaid commitment and other fees of $1,553 payable in connection with the committed equity facility, (iii) deferred purchase consideration of $2,323 related to our acquisitions of EMI Solutions and RaGE Systems, payable at various dates through June 2025, and (iv) potential payments of up to $8,000 under the RaGE Earn-out, payable at various dates through March 2026.

 

36

 

Going Concern

 

We incurred a loss from operations of $14,630 for the three months ended December 31, 2024, and we incurred losses from operations of $46,395 and $35,544 for the years ended September 30, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $124,296. We have historically financed our operations through the issuance and sale of equity securities and the issuance of debt. We expect to continue to incur operating losses and negative cash flows from operations for the foreseeable future and will need to raise additional debt or equity financing to fund our continuing operations, product development plans and capital expenditure requirements, to service our debt obligations and to make strategic investments. We believe that there is substantial doubt concerning our ability to continue as a going concern as we currently do not have adequate liquidity to meet our operating needs and satisfy our obligations beyond the next approximately ninety days.

 

While we will seek to raise additional capital, we cannot assure you that we will be able to obtain financing on acceptable terms, or at all, to provide the necessary interim funding to continue our operations and satisfy our obligations. If we raise funds by issuing equity securities, dilution to our existing stockholders may result. Any equity securities we issue may also provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, such debt securities would have rights, preferences and privileges senior to those of preferred and common stockholders. The terms of debt securities or borrowings may impose significant restrictions on our operations. The capital markets have in the past, and may in the future, experience periods of volatility that could impact the availability and cost of equity and debt financing. In addition, potential future increases in federal fund rates set by the Federal Reserve, which serve as a benchmark for rates on borrowing, could adversely impact the cost or availability of debt financing.

 

If we are unable to obtain additional financing, or if such transactions are successfully completed but do not provide adequate financing, we will not be able to continue operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties. Accordingly, the financial statements have been prepared on a basis that assumes we will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.

 

Critical Accounting Policies and Estimates

 

The preparation of our financial statements and related disclosures in accordance with U.S. GAAP requires that we make judgments, assumptions and estimates that affect the amounts reported in the unaudited condensed consolidated financial statements.

 

The methods, estimates and judgments we use in applying our accounting policies have a significant impact on the results that we report in our financial statements. Some of our accounting policies require that we make difficult and subjective judgments, often as a result of the need to make estimates regarding matters that are inherently uncertain. We base our estimates and judgments on historical experience, current economic and industry conditions and other factors that we believe to be reasonable under the circumstances. Actual results may differ from our estimates under different assumptions or conditions.

 

Our most critical accounting estimates include the assumptions we use in the determination of the fair value of the earnout liability, the fair value of the PIPE make-whole liability, the fair value of common stock, stock-based compensation, the fair value of liability-classified warrants, the provision for income taxes, the accounting for business combinations and the measurement of definite-lived intangible assets and goodwill.

 

Fair Value of Earnout Liability

 

We account for the earnout shares as liability-classified instruments because the events that determine the number of earnout shares to which the earnout recipients will be entitled include events that are not solely indexed to our common stock. We remeasure the earnout liability to its estimated fair value at the end of each reporting period.

 

37

 

We estimate the fair value of the earnout liability using a Monte Carlo simulation model that utilizes significant assumptions, including volatility, expected term and risk-free rate that determine the probability of achieving the earnout conditions. The following table summarizes the assumptions used in estimating the fair value of the earnout liability at the respective dates:

 

    December 31,
2024
    September 30,
2024
 
Stock price   $ 1.70     $ 1.06  
Expected volatility     75 %     70 %
Risk-free rate     4.4 %     3.6 %
Contractual term     7.0 years       7.2 years  

 

Fair Value of Common Stock

 

The fair value of our common stock affects the accounting for, and measurement of, a number of transactions, including awards of stock-based compensation, sales of our common and preferred stock or warrants to purchase our common stock and business combinations. For periods subsequent to the Merger, we determine the fair value of our common stock based on quoted market prices. For periods prior to the Merger, there was no public market for our common stock and we determined the fair value of our common stock considering a number of objective and subjective factors, including: third-party valuations of our common stock, the valuation of comparable companies, sales of our common stock to outside investors in arms-length transactions, our forecasted financial performance, operational developments and milestones, the lack of marketability of our common stock, the likelihood of achieving a liquidity event, and the general and industry specific economic outlook, among other factors. We determined the fair value of our common stock in accordance with applicable elements of the American Institute of Certified Public Accountants guide, Valuation of Privately Held Company Equity Securities Issued as Compensation.

 

The assumptions underlying our valuations represented our best estimates, which involve inherent uncertainties and the application of judgment. As a result, if factors or expected outcomes had changed, or if we had used significantly different assumptions or estimates, our stock-based compensation expense and equity-based valuations or the value of the business we acquired could have been materially different.

 

Stock-Based Compensation

 

Our stock-based compensation awards include stock options and restricted stock units. In some cases, other equity transactions, such as the sale of warrants to purchase our common stock are accounted for as equity-classified awards granted to employees. In each case, we must determine the fair value of the equity-based awards.

 

We estimate the fair value of stock options and warrants to purchase our common stock using the Black-Scholes-Merton (“Black-Scholes”) option-pricing model. The Black-Scholes option pricing model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include:

 

  the per share fair value of the underlying common stock;
  the exercise price;
  the risk-free interest rate;
  the expected term;
  expected stock price volatility over the expected term; and
  the expected annual dividend yield.

 

We recognize the fair value of each stock option award as compensation expense on a straight-line basis over the requisite service period, which is typically four years. We have elected to account for forfeitures as they occur and initially record stock-based compensation expense assuming all option holders will complete the requisite service period. If an employee forfeits an award because they fail to complete the requisite service period, we will reverse previously recognized stock-based compensation expense in the period the award is forfeited.

 

Our restricted stock units entitle the holder to receive a number of shares of our common stock. The majority of our restricted stock units are subject to both service-based vesting conditions and performance conditions. We establish the fair value of each restricted stock unit based on the grant-date fair value of the underlying shares of our common stock. Our accounting for restricted stock units also requires that we evaluate the probability of achievement of applicable performance conditions. When we conclude that the achievement of a performance condition is not probable, we do not recognize any compensation cost for the restricted stock unit. We continually reevaluate the probability of achievement of performance conditions. If we subsequently determine the achievement of a performance condition is probable, we will be required to record a “catch-up” of previously unrecognized stock-based compensation expense, subject to any applicable time-based vesting.

 

38

 

We have also issued warrants to purchase common stock to employees and service providers in exchange for services to us and we determined that those warrants should be accounted for as equity-classified awards. We determined the fair value of these warrants at the date of issuance using the Black- Scholes option pricing model, based on the variables and assumptions discussed above, and recognized the fair value as stock-based compensation expense in our consolidated statements of operations and comprehensive income (loss).

 

We classify stock-based compensation expense in our consolidated statements of operations and comprehensive income (loss) in the same manner in which the award recipient’s salary and related costs are classified or in which the award recipient’s service payments are classified. In future periods, we expect stock-based compensation expense to increase, due in part to our existing unrecognized stock-based compensation expense and as we grant additional stock-based awards to continue to attract and retain employees.

 

Provision for Income Taxes

 

We account for income taxes using the asset and liability method, whereby deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. We recognize the effect of a change in tax laws on deferred tax assets and liabilities in our results of operations in the period the new laws are enacted. We record a valuation allowance to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such assets will be realized.

 

We recognize liabilities for uncertain tax positions based on a two-step process regarding recognition and measurement. We recognize a tax benefit only if it is more likely than not the tax position will be sustained on examination by the local taxing authorities based on the technical merits of the position. We measure the amount of tax benefits recognized in the financial statements from such positions based on the largest benefit greater than 50% likely to be realized upon ultimate settlement with the related tax authority. Changes in recognition or measurement of an uncertain tax position are reflected in our statements of operations and comprehensive income (loss) in the period in which the change in estimate occurs, based on new information not previously available.

 

Business Combinations

 

We allocate the purchase price of an acquisition to the tangible and intangible assets acquired and the liabilities assumed based on their estimated fair values. The excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill.

 

Accounting for business combinations requires that we make significant estimates and assumptions to determine the fair value of assets acquired and liabilities assumed at the acquisition date. Although we believe the assumptions and estimates we use to be reasonable and appropriate, they are inherently uncertain. Critical estimates in valuing certain acquired assets may include, but are not limited to, expected future cash flows including revenue growth rate assumptions from product sales, customer contracts and acquired technologies, the expected costs to develop acquired technology into commercially viable products and the estimated cash flows from the projects when completed, including assumptions associated with the technology migration curve and expected selling, general and administrative costs. We derive the discount rates used to discount expected future cash flows to present value using a weighted-average cost of capital analysis adjusted to reflect inherent risks. Unanticipated events and circumstances may occur that could affect either the accuracy or validity of these assumptions, estimates or actual results.

 

Intangible Assets and Goodwill

 

We have definite-lived acquisition-related intangible assets consisting of developed technology, customer relationships, tradenames and backlog. We record amortization expense associated with each definite-lived acquisition-related intangible asset based on its estimated useful life. We also review our acquisition-related intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. This includes our regular review of our operating performance for indicators of impairment. Factors considered important that could trigger an impairment review include a significant underperformance relative to expected historical or projected future operating results, or a significant change in the manner of the use of the acquisition-related intangible assets.

 

39

 

We perform impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of the acquisition-related intangible asset is determined by comparing the forecasted undiscounted cash flows attributable to such acquisition-related intangible asset, including any cash flows upon their eventual disposition, to its carrying value. If the carrying value of the acquisition-related intangible asset exceeds the forecasted undiscounted cash flows, then the acquisition-related intangible asset is written down to its fair value.

 

We also have goodwill totaling $16,066 as of December 31, 2024, which represents the excess of the fair value of purchase consideration of an acquired business over the fair value of the identifiable net assets acquired. Goodwill is not amortized, but we test goodwill for impairment at a reporting unit level on an annual basis on July 31, or more frequently if circumstances change or an event occurs that would more likely than not reduce the fair value of a reporting unit below its carrying amount.

 

We assess all relevant qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the assessment indicates that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, a quantitative goodwill impairment test is not necessary. If the assessment of all relevant qualitative factors indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, we would perform a quantitative goodwill impairment test. The quantitative impairment test for goodwill consists of a comparison of the fair value of a reporting unit with its carrying value, including the goodwill allocated to that reporting unit. If the carrying value of a reporting unit exceeds its fair value, we will recognize an impairment loss equal to the amount of the excess, limited to the amount of goodwill allocated to that reporting unit.

 

Our impairment tests require the use of judgment, including the identification of, and assignment of assets and liabilities to, asset groups and/or reporting units and the determination of fair values of asset groups or reporting units. We also must make significant assumptions and estimates, including the amount and timing of future cash flows, discount rates, asset fair values and the expected useful lives of the acquisition-related intangible assets. To make these judgments and estimates, we may use internal undiscounted cash flow estimates, quoted market prices (if available) or other available data.

 

We did not recognize any impairment charges during the three months ended December 31, 2024 and 2023. However, future cash flows may vary from what was expected, or assumptions and estimates we use in the fair value calculations may change. Any such changes in assumptions or estimates could change the estimates of future cash flows we use to estimate fair values and could result in a decline in the estimated fair value of related assets. Such a decline in our estimates of the fair values of assets may result in future impairment charges.

 

Emerging Growth Company

 

We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and we will take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.

 

40

 

Smaller Reporting Company

 

Additionally, we are a “smaller reporting company,” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the last business day of our second fiscal quarter, or (ii) our annual revenue exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the last business day of our second fiscal quarter. If we continue to be a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from these certain reduced disclosure requirements that are available to smaller reporting companies.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

 

Item 4. Controls and Procedures.

 

Limitations on Effectiveness of Disclosure Controls and Procedures

 

In designing and evaluating our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures, pursuant to Rule 13a-15(b) of the Exchange Act, as of December 31, 2024. We identified material weaknesses in our internal control over financial reporting as described below, and, as a result, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective as of December 31, 2024.

 

Material Weaknesses in Internal Control over Financial Reporting

 

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses are as follows:

 

  We did not design and maintain an effective control environment commensurate with our financial reporting requirements. Specifically, we lacked a sufficient complement of personnel with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately. Additionally, our insufficient complement of personnel resulted in an inability to consistently establish appropriate authorities and responsibilities in pursuit of financial reporting objectives, as demonstrated by, among other things, insufficient segregation of duties in our finance and accounting functions.
  We did not design and maintain an effective risk assessment process at a precise enough level to identify new and evolving risks of material misstatement in our financial statements. Specifically, changes to existing controls or the implementation of new controls have not been sufficient to respond to changes to our risks of material misstatement to financial reporting.

 

41

 

These material weaknesses contributed to the following additional material weaknesses:

 

  We did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over (i) the preparation and review of account reconciliations and journal entries, (ii) maintaining appropriate segregation of duties, (iii) determining the appropriate grant date for stock options and evaluating the assumptions used within our Black-Scholes model to determine the fair value of option grants, and (iv) the review of the completeness and accuracy of the income tax provision and related disclosures. Additionally, we did not design and maintain controls over the classification and presentation of accounts and disclosures in our financial statements and to ensure revenue transactions are recorded in the correct period.
  We did not design and maintain effective controls to identify and account for certain non-routine, unusual or complex transactions, including the proper application of U.S. GAAP of such transactions. Specifically, we did not design and maintain effective controls to (i) timely identify, account for and value business combinations and asset acquisitions, including the associated tax implications and (ii) timely identify, account for and value our financing arrangements.
  We did not design and maintain effective controls to verify transactions are properly authorized, executed, and accounted for, including transactions related to incentive compensation arrangements.

 

These material weaknesses resulted in adjustments to revenue, accrued expenses, general and administrative expenses, inventory, costs of products sold, the accounting for and classification of redeemable convertible preferred stock, founders preferred and common stock, stock-based compensation expense, other current assets, income tax expense and deferred tax liabilities, as well as the purchase price allocation for our business combination, as of and for the years ended September 30, 2022 and 2021; and, adjustments to stock-based compensation expense, accrued expenses, other current liabilities and the PIPE make-whole liability, as well as the purchase price allocations for our business combinations as of and for the interim periods ended December 31, 2023 and June 30, 2024, and as of and for the year ended September 30, 2024.

 

  We did not design and maintain effective information technology (“IT”) general controls for information systems that are relevant to the preparation of our financial statements. Specifically, we did not design and maintain (i) program change management controls to ensure that program and data changes are identified, tested, authorized and implemented appropriately, (ii) user access controls to ensure appropriate segregation of duties and to adequately restrict user and privileged access to appropriate personnel, (iii) computer operations controls to ensure that processing and transfer of data, and data backups and recovery are monitored, and (iv) program development controls to ensure that new software development is tested, authorized and implemented appropriately. These deficiencies did not result in a misstatement to our financial statements.

 

Additionally, these material weaknesses could result in a misstatement of substantially all of our accounts or disclosures that would result in a material misstatement to our annual or interim financial statements that would not be prevented or detected.

 

Remediation Plan

 

We have begun an implementation plan to remediate these material weaknesses, which we expect will result in significant future costs for us.

 

42

 

Those remediation measures will include (i) hiring additional accounting and IT personnel to enhance our financial reporting, accounting and IT capabilities; (ii) designing and implementing controls to formalize roles and review responsibilities and designing and implementing controls over segregation of duties; (iii) designing and implementing controls to identify and evaluate changes in our business and the impact on our internal control over financial reporting; (iv) designing and implementing controls over the proper authorization of transactions; (v) designing and implementing controls to identify, account for, and value non-routine, unusual or complex transactions; (vi) designing and implementing formal accounting policies, procedures and controls supporting our financial close process, including controls over account reconciliations and journal entries; (vii) designing and implementing controls over determining the appropriate grant date for stock options and evaluating the assumptions used within the Black-Scholes model; (viii) designing and implementing controls over the completeness and accuracy of the income tax provision and related disclosure; (ix) designing and implementing controls over the classification and presentation of accounts and disclosures in our financial statements and to ensure revenue transactions are recorded in the correct period; (x) implementing a more sophisticated IT system; and (xi) designing and implementing IT general controls.

 

The material weaknesses will not be considered remediated until our remediation plan as described above has been fully implemented and we determine no further changes to the remediation plan are necessary, the applicable controls operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls are operating effectively.

 

Notwithstanding the above, our management believes that the financial statements included in this Quarterly Report on Form 10-Q present fairly in all material respects our financial position, results of operations and cash flows for the periods presented.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

43

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

Refer to Note 13—Commitments and Contingencies of the notes to our unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for disclosures regarding legal proceedings.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

In connection with the settlement of litigation, on October 11, 2024, we agreed to issue a warrant to purchase 250,000 shares of Class A Common Stock to a former employee. Such warrants have an exercise price of $0.01 per share.

 

On November 25, 2024 and December 20, 2024, we agreed that two outstanding notes payable with an aggregate principal balance of $500,000, plus accrued interest of $45,896, would be converted into an aggregate of 631,805 shares of Class A Common Stock.

 

On December 4, 2024, we agreed to issue 40,000 shares of Class A Common Stock to two of our vendors in exchange for services rendered to us.

 

On December 26, 2024, we agreed to sell 521,739 shares of Class A Common Stock to an accredited investor for an aggregate of $600,000.

 

No underwriting discounts and commissions were paid with respect to the foregoing transactions. The issuances of the securities were made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

 

Item 5. Other Information.

 

(c) During the three months ended December 31, 2024, none of our officers (as defined in Rule 16a-1(f) of the Exchange Act) or directors adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

44

 

Item 6. Exhibits.

 

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

 

Exhibit No.   Description
     
31.1   Certification of Principal Executive Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934.
     
31.2   Certification of Principal Financial Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934.
     
32.1   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101 INS   Inline XBRL Instance Document.
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

45

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MOBIX LABS, INC.
   
Date: February 12, 2025 By: /s/ Keyvan Samini
    Keyvan Samini
   

President and Chief Financial Officer

(Principal Financial Officer and Duly Authorized Officer)

 

46

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Fabrizio Battaglia, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended December 31, 2024 of Mobix Labs, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 12, 2025 By: /s/ Fabrizio Battaglia
    Fabrizio Battaglia
    Chief Executive Officer
    (Principal Executive Officer)

 

 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Keyvan Samini, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended December 31, 2024 of Mobix Labs, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 12, 2025 By: /s/ Keyvan Samini
    Keyvan Samini
    President and Chief Financial Officer
    (Principal Financial Officer)

 

 

 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Mobix Labs, Inc. (the “Registrant”) on Form 10-Q for the quarter ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, in the capacity and on the date indicated below, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

Date: February 12, 2025 By: /s/ Fabrizio Battaglia
    Fabrizio Battaglia
    Chief Executive Officer
    (Principal Executive Officer)

 

 

 

EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Mobix Labs, Inc. (the “Registrant”) on Form 10-Q for the quarter ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, in the capacity and on the date indicated below, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

Date: February 12, 2025 By: /s/ Keyvan Samini
    Keyvan Samini
    President and Chief Financial Officer
    (Principal Financial Officer)